| Cat. No. |
Product Name |
Immunogen |
Isotype |
| 10-134 |
14F7 (ganglioside
N-glycolyl GM3) |
Mus musculus /
ganglioside N-glycolyl GM3 [Homo sapiens] |
IgG1-kappa |
| 10-137 |
Abagovomab
(idiotope of anti-Mus musculus monoclonal antibody OC126) |
Mus musculus /
idiotope of anti- Mus musculus monoclonal antibodyOC126 [Homo sapiens] |
IgG1-kappa |
| 10-167 |
Abciximab
(ITGA2B_ITGB3) |
Chimeric /
ITGA2B_ITGB3 [Homo sapiens] |
Fab-G1-kappa |
| 10-905 |
Abelacimab (F11) |
Homo sapiens / F11
[Homo sapiens] |
IgG1-lambda |
| 10-654 |
Abituzumab (ITGAV
/CD51) |
Humanized / ITGAV
/CD51 [Homo sapiens] |
IgG2-kappa |
| 10-886 |
Abrezekimab (IL13) |
Humanized / IL13
[Homo sapiens] |
Fab-G1-kappa |
| 10-660 |
Abrilumab
(ITGA4_ITGB7) |
Homo sapiens /
ITGA4_ITGB7 [Homo sapiens] |
IgG2-kappa |
| 10-184 |
ABX-IL8 (IL8) |
Homo sapiens / IL8
[Homo sapiens] |
IgG2-nd |
| 21-881 |
Acapatamab |
Chimeric, Humanized
/ FOLH1, CD3E |
Bispecific
scFv;Kappa;Lambda |
| 21-882 |
Acasunlimab |
Humanized / CD274,
TNFRSF9 |
Bispecific
IgG1;Lambda;Kappa |
| 10-483 |
Actoxumab (toxin A) |
Homo sapiens /
toxin A [Clostridium difficile] |
IgG1-kappa |
| 10-186 |
Adalimumab
(TNFSF2/TNF-alpha/TNFA) |
Homo sapiens /
TNFSF2/TNF-alpha/TNFA [Homo sapiens] |
IgG1-kappa |
| 10-185 |
Adecatumumab
(EPCAM) |
Homo sapiens /
EPCAM [Homo sapiens] |
IgG1-nd |
| 10-629 |
Aducanumab
(APP Abeta) |
Homo sapiens / APP
Abeta [Homo sapiens] |
IgG1-kappa |
| 10-744 |
Afasevikumab (IL17A
/IL17F) |
Homo sapiens /
IL17A /IL17F [Homo sapiens] |
IgG1-kappa |
| 21-879 |
Aflibercept |
Humanized / VEGFA
[Homo sapiens] |
Human IgG1 |
| 10-188 |
Al-901 (IGHE) |
Homo sapiens / IGHE
[Homo sapiens] |
|
| 10-255 |
Alacizumab
(KDR/VEGFR2/CD309) |
Humanized /
KDR/VEGFR2/CD309 [Homo sapiens] |
di-Fab' |
| 10-049 |
Alemtuzumab (CD52) |
Humanized / CD52
[Homo sapiens] |
IgG1-kappa |
| 10-168 |
Alg-991 (Urushiol) |
Chimeric / Urushiol
[Toxicodendron] |
IgM-nd |
| 10-485 |
Alirocumab (PCSK9) |
Homo sapiens /
PCSK9 [Homo sapiens] |
IgG1-kappa |
| 21-884 |
Alnuctamab |
Humanized /
TNFRSF17, CD3E |
Bispecific
,IgG1;IgG1,Kappa;Lambda |
| 21-883 |
Alomfilimab |
Homo sapiens / ICOS |
IgG1，Kappa |
| 24-390 |
alpha 5 beta 1
Integrin Antibody [M200 (Volociximab)], Human IgG4 |
Heterodimeric
α5β1Fc
fusion protein |
IgG4 kappa |
| 24-391 |
alpha 5 beta 1
Integrin Antibody [M200 (Volociximab)], Rabbit IgG |
Heterodimeric
α5β1Fc
fusion protein |
IgG kappa |
| 10-327 |
Altumomab
(CEACAM5/CD66e) |
Mus musculus /
CEACAM5/CD66e [Homo sapiens] |
IgG1-nd |
| 10-086 |
Amatuximab (MSLN) |
Chimeric / MSLN
[Homo sapiens] |
IgG1-kappa |
| 10-966 |
Amivantamab
(EGFR/ME/RCCP2) |
Homo sapiens /
EGFR/ME/RCCP2 [Homo sapiens] |
IgG1-kappa |
| 21-885 |
Amlitelimab |
Humanized / TNFSF4 |
IgG4,Kappa |
| 10-298 |
Anatumomab
Mafenatox (TAG-72) |
Mus musculus /
TAG-72 [Homo sapiens] |
Fab-G1-kappa |
| 21-886 |
Anbenitamab |
Humanized / ERBB2
(Domain II), ERBB2 (Domain IV) |
Bispecific
,IgG1;Kappa;Kappa |
| 10-684 |
Andecaliximab
(MMP9) |
Chimeric / MMP9
[Homo sapiens] |
IgG4-kappa |
| 10-614 |
Anetumab Ravtansine
(MSLN) |
Homo sapiens / MSLN
[Homo sapiens] |
IgG1-lambda |
| 10-624 |
Anifrolumab
(IFNAR1) |
Homo sapiens /
IFNAR1 [Homo sapiens] |
IgG1-kappa |
| 10-253 |
Anrukinzumab (IL13) |
Humanized / IL13
[Homo sapiens] |
IgG1-kappa |
| 21-872 |
Ansuvimab |
Humanized / GP1
surface protein of Ebolavirus |
IgG1 |
| 21-877 |
Anti CD146/MUC18
(c3.19.1) |
Humanized /
CD146/MUC18 [Homo sapiens] |
Human IgG2 |
| 21-876 |
Anti IL1RL1/ST2
(STLM208) |
Humanized /
IL1RL1/ST2 [Homo sapiens] |
Human IgG |
| 21-875 |
Anti
IL1RL1/ST2(C2244) |
Humanized /
IL1RL1/ST2 [Homo sapiens] |
Human IgG |
| 21-863 |
Anti NS1 of dengue
virus |
Humanized / Dengue
virus |
Human IgG1 |
| 21-861 |
Anti-CD28 |
Humanized / CD28
(Tp44) [Homo sapiens] |
Human IgG4 |
| 21-860 |
Anti-CLDN18.2 |
|
Mouse IgG1 |
| 21-862 |
Anti-LGR4 |
Humanized / LGR4 (
G protein-coupled receptor 48, G protein-coupled receptor GPR48, G-protein
coupled receptor 48, leucine-rich repeat containing G protein-coupled
receptor 4, Leucine-rich repeat-containing G-protein coupled receptor 4)
[Homo sapiens] |
Human IgG1 |
| 10-067 |
Apolizumab
(HLA-DRB) |
Humanized / HLA-DRB
[Homo sapiens] |
IgG1-nd |
| 10-794 |
Aprutumab (FGFR2) |
Homo sapiens /
FGFR2 [Homo sapiens] |
IgG1-lambda |
| 10-139 |
Arcitumomab
(CEACAM5/CD66e) |
Mus musculus /
CEACAM5/CD66e [Homo sapiens] |
Fab'-G1-nd |
| 10-730 |
Ascrinvacumab
(ACVRL1/SKR3/TGF-B/ TSR-I) |
Homo sapiens /
ACVRL1/SKR3/TGF-B/ TSR-I [Homo sapiens] |
IgG2-kappa |
| 10-287 |
Aselizumab
(SELL/CD62L ) |
Humanized /
SELL/CD62L [Homo sapiens] |
IgG4-nd |
| 10-968 |
Astegolimab
(IL1RL1) |
Homo sapiens /
IL1RL1 [Homo sapiens] |
IgG2-kappa |
| 10-678 |
Atezolizumab
(CD274/B7-H1/PDL1) |
Humanized /
CD274/B7-H1/PDL1 [Homo sapiens] |
IgG1-kappa |
| 10-854 |
Atidortoxumab
(alpha toxin) |
Homo sapiens /
alpha toxin [Staphylococcus aureus];bi-component leukocidins [Staphylococcus
aureus] |
IgG1-kappa |
| 10-445 |
Atinumab
(RTN4/NOGO) |
Homo sapiens /
RTN4/NOGO [Homo sapiens] |
IgG4-kappa |
| 10-959 |
Atoltivimab (Zaire
Ebola virus) |
Homo sapiens /
Zaire Ebola virus [Zaire ebolavirus] |
IgG1-kappa |
| 10-969 |
Avdoralimab (C5AR1) |
Homo sapiens /
C5AR1 [Homo sapiens] |
IgG1-kappa |
| 10-672 |
Avelumab
(CD274/B7-H1/PDL1) |
Homo sapiens /
CD274/B7-H1/PDL1 [Homo sapiens] |
IgG1-lambda |
| 10-970 |
Avizakimab (IL21) |
Humanized / IL21
[Homo sapiens] |
IgG1-kappa |
| 10-971 |
Axatilimab
(CSF1R/CD115) |
Humanized /
CSF1R/CD115 [Homo sapiens] |
IgG4-kappa |
| 10-829 |
Azintuxizumab
(SLAMF7/CRACC/CD319) |
Chimeric,Humanized
/ SLAMF7/CRACC/CD319 [Homo sapiens] |
IgG1-kappa |
| 10-947 |
Balstilimab
(PDCD1/PD1/CD279) |
Homo sapiens /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 21-868 |
Bamlanivimab |
Humanized / RBD
[SARS-CoV-2] |
Human IgG |
| 21-887 |
Bamlanivimab |
Homo sapiens /
SARS-CoV-2 Spike |
IgG1,Kappa |
| 10-270 |
Bapineuzumab (APP
Abeta) |
Humanized / APP
Abeta [Homo sapiens] |
IgG1-nd |
| 21-888 |
Bapotulimab |
Homo sapiens /
ILDR2 |
IgG2,Kappa |
| 21-889 |
Barecetamab |
Homo sapiens /
ERBB3 |
IgG1，Lambda |
| 10-169 |
Basiliximab
(IL2RA/CD25) |
Chimeric /
IL2RA/CD25 [Homo sapiens] |
IgG1-kappa |
| 11-012 |
Basilixumab (IL-2
receptor) |
|
IgG1k |
| 10-972 |
Batoclimab (FCGRT) |
Homo sapiens /
FCGRT [Homo sapiens] |
IgG1-lambda |
| 10-170 |
Bavituximab
(Phosphatidylserine) |
Chimeric /
Phosphatidylserine [Homo sapiens] |
IgG1-kappa |
| 10-957 |
Bedinvetmab
(NGF/NGFB) |
Caninized /
NGF/NGFB [Canis lupus familiaris] |
IgG2-lambda |
| 10-973 |
Befovacimab (TFPI ) |
Homo
sapiens,Humanized / TFPI [Homo sapiens] |
IgG2-lambda |
| 10-668 |
Begelomab
(DPP4/TP103/CD26) |
Mus musculus /
DPP4/TP103/CD26 [Homo sapiens] |
IgG2b-kappa |
| 10-899 |
Belantamab
(TNFRSF17/CD269) |
Humanized /
TNFRSF17/CD269 [Homo sapiens] |
IgG1-kappa |
| 10-282 |
Belimumab
(TNFSF13B/CD257) |
Homo sapiens /
TNFSF13B/CD257 [Homo sapiens] |
IgG1-lambda |
| 10-861 |
Bemarituzumab
(FGFR2) |
Humanized / FGFR2
[Homo sapiens] |
IgG1-kappa |
| 10-346 |
Benralizumab
(IL5RA/CD12) |
Humanized /
IL5RA/CD12 [Homo sapiens] |
IgG1-kappa |
| 10-974 |
Benufutamab
(TNFRSF10B/TRAILR2/ CD262) |
Chimeric,Humanized
/ TNFRSF10B/TRAILR2/ CD262 [Homo sapiens] |
IgG1-kappa |
| 10-855 |
Berlimatoxumab
(LukGH) |
Homo sapiens /
LukGH [Staphylococcus aureus] |
IgG1-kappa |
| 10-694 |
Bermekimab (IL1A) |
Humanized / IL1A
[Homo sapiens] |
IgG1-kappa |
| 10-882 |
Bersanlimab
(ICAM1/CD54) |
Homo sapiens /
ICAM1/CD54 [Homo sapiens] |
IgG1-lambda |
| 10-191 |
Bertilimumab
(CCL11) |
Homo sapiens /
CCL11 [Homo sapiens] |
IgG4-kappa |
| 10-275 |
Besilesomab
(CEACAM8/CD66b) |
Mus musculus /
CEACAM8/CD66b [Homo sapiens] |
IgG1-kappa |
| 10-068 |
Bevacizumab (VEGFA) |
Humanized / VEGFA
[Homo sapiens] |
IgG1-kappa |
| 10-484 |
Bezlotoxumab (toxin
B) |
Homo sapiens /
toxin B [Clostridium difficile] |
IgG1-kappa |
| 10-154 |
Biciromab (Fibrin
II beta chain,fibrin) |
Mus musculus /
Fibrin II beta chain,fibrin [Homo sapiens] |
Fab'-G1-kappa |
| 10-587 |
Bimagrumab
(ACVR2A/ACVR2B) |
Homo sapiens /
ACVR2A/ACVR2B [Homo sapiens] |
IgG1-lambda |
| 10-652 |
Bimekizumab (IL17A) |
Humanized / IL17A
[Homo sapiens] |
IgG1-kappa |
| 10-776 |
Birtamimab (SAA1) |
Chimeric,Humanized
/ SAA1 [Homo sapiens] |
IgG1-kappa |
| 10-295 |
Bivatuzumab (CD44
/CD44V) |
Humanized / CD44
/CD44V [Homo sapiens] |
IgG1-kappa |
| 10-732 |
Bleselumab (CD40/
TNFRSF5) |
Homo sapiens /
CD40/ TNFRSF5 [Homo sapiens] |
IgG4-kappa |
| 10-128 |
Blinatumomab
(CD19/CD3E) |
Mus musculus /
CD19/CD3E [Homo sapiens] |
(scFv-kappa-heavy)-(scFv-heavy-kappa) |
| 10-462 |
Blosozumab
(SOST(sclerostin)) |
Humanized /
SOST(sclerostin) [Homo sapiens] |
IgG4-kappa |
| 21-852 |
BMS-986253,
HuMax-IL8, HuMax-Inflam/MDX018 |
Humanized / IL-8
(Granulocyte chemotactic protein 1, Monocyte-derived neutrophil-activating
peptide, IL-8 (1-77), IL-8 (9-77), Monocyte-derived neutrophil chemotactic
factor, IL-8 (7-77), (Ser-IL-8)72, GCP/IL-8 protein V, MONAP, C-X-C motif
chemokine 8, GCP/IL-8 protein I, Neutrophil-ac ) [Homo sapiens] |
IgG1 |
| 10-651 |
Bococizumab
(PCSK9/NARC1/ PC9) |
Humanized /
PCSK9/NARC1/ PC9 [Homo sapiens] |
IgG2-kappa |
| 21-890 |
Botensilimab |
Homo sapiens /
CTLA4 |
IgG1，Kappa |
| 10-804 |
Brazikumab (IL23A) |
Homo sapiens /
IL23A [Homo sapiens] |
IgG2-lambda |
| 21-857 |
Brentuximab |
Humanized / TNFRSF8
(CD30, D1S166E, Ki-1) [Homo sapiens] |
Human IgG1 |
| 10-183 |
Briakinumab (IL12B) |
Homo sapiens /
IL12B [Homo sapiens] |
IgG1-lambda |
| 10-463 |
Brodalumab
(IL17RA/CD217) |
Homo sapiens /
IL17RA/CD217 [Homo sapiens] |
IgG2-kappa |
| 10-687 |
Brolucizumab
(VEGFA) |
Humanized / VEGFA
[Homo sapiens] |
scFv-kappa-heavy |
| 10-657 |
Brontictuzumab
(NOTCH1) |
Humanized / NOTCH1
[Homo sapiens] |
IgG2-lambda |
| 10-906 |
Budigalimab
(PDCD1/PD1/CD279) |
Chimeric,Humanized
/ PDCD1/PD1/CD279 [Homo sapiens] |
IgG1-kappa |
| 10-786 |
Burosumab (FGF23) |
Homo sapiens /
FGF23 [Homo sapiens] |
IgG1-kappa |
| 11-054 |
Cabiralizumab
(CSF1R/CD115) |
Humanized /
CSF1R/CD115 [Homo sapiens] |
IgG4-kappa |
| 21-891 |
Cadonilimab |
Humanized / PDCD1,
CTLA4 |
Bispecific
,IgG1;Kappa;Lambda |
| 10-250 |
Camidanlumab
(IL2RA/CD25) |
Homo sapiens /
IL2RA/CD25 [Homo sapiens] |
IgG1-kappa |
| 10-141 |
Campath-9H (CD4) |
Mus
musculus,Humanized / CD4 [Homo sapiens] |
IgG1-kappa |
| 10-798 |
Camrelizumab
(PDCD1/PD-1/CD279) |
Humanized /
PDCD1/PD-1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-265 |
Canakinumab (IL1B) |
Homo sapiens / IL1B
[Homo sapiens] |
IgG1-kappa |
| 10-082 |
Cantuzumab
Mertansine (CA242) |
Humanized / CA242
[Homo sapiens] |
IgG1-kappa |
| 10-476 |
Caplacizumab
(VWF A1 domain) |
Humanized / VWF A1
domain [Homo sapiens] |
VH-VH |
| 24-278 |
carcinoembryonic
antigen (CEA) Antibody [Arcitumomab], Human IgG1 |
Carcinoembryonic
antigen (CEA) describes a set of highly related glycoproteins involved in
cell adhesion normally produced in gastrointestinal tissue during fetal
development, but only at very low levels in adults. |
IgG1 kappa |
| 24-279 |
carcinoembryonic
antigen (CEA) Antibody [Arcitumomab], Rabbit IgG |
Carcinoembryonic
antigen (CEA) describes a set of highly related glycoproteins involved in
cell adhesion normally produced in gastrointestinal tissue during fetal
development, but only at very low levels in adults. |
IgG kappa |
| 10-446 |
Carlumab
(CCL2/MCP-1/MCAF/SCYA2) |
Homo sapiens /
CCL2/MCP-1/MCAF/SCYA2 [Homo sapiens] |
IgG1-kappa |
| 10-769 |
Carotuximab (ENG) |
Chimeric / ENG
[Homo sapiens] |
IgG1-kappa |
| 21-892 |
Casirivimab |
Homo sapiens /
SARS-CoV-2 Spike RBD |
IgG1，Kappa |
| 10-171 |
cBR96 (Lewis Y) |
Chimeric,Humanized
/ Lewis Y [Homo sapiens] |
IgG1-kappa, |
| 24-490 |
CCR4 Antibody
[KW-0761 (Mogamulizumab)], Rabbit IgG |
This antibody was
prepared by humanization of a mouse anti-CCR4 mAb. |
IgG kappa |
| 24-427 |
CD11a Antibody
[hu1124 (Efalizumab)], Human IgG1 |
Efalizumab binds to
CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed
on all leukocytes. |
IgG1 kappa |
| 24-428 |
CD11a Antibody
[hu1124 (Efalizumab)], Rabbit IgG |
Efalizumab binds to
CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed
on all leukocytes. |
IgG kappa |
| 24-803 |
CD154 Antibody
[IDEC-131 (Toralizumab)], Mouse IgG1 |
The original
monoclonal antibody was generated by immunization with a soluble fusion
protein of human gp39 (gp39-CD8). |
IgG1 kappa |
| 24-804 |
CD154 Antibody
[IDEC-131 (Toralizumab)], Rabbit IgG |
The original
monoclonal antibody was generated by immunization with a soluble fusion
protein of human gp39 (gp39-CD8). |
IgG kappa |
| 24-125 |
CD20 Antibody
[10F381 (rituximab)], Human IgG1 |
Human
lymphoblastoid cell line SB. |
IgG1 kappa |
| 24-126 |
CD20 Antibody
[10F381 (rituximab)], Rabbit IgG |
Human
lymphoblastoid cell line SB. |
IgG kappa |
| 24-491 |
CD22 Antibody [hL22
(Epratuzumab)], Human IgG1 |
This antibody was
prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised
against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the
molecule, with the remainder being human framework sequences, which greatly
reduces the potential for immunogenicity (Traczewski, 2010). |
IgG1 kappa |
| 24-492 |
CD22 Antibody [hL22
(Epratuzumab)], Rabbit IgG |
This antibody was
prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised
against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the
molecule, with the remainder being human framework sequences, which greatly
reduces the potential for immunogenicity (Traczewski, 2010). |
IgG kappa |
| 24-282 |
CD33 Antibody
[hP67.6 (Gemtuzumab)], Human IgG4 |
Gemtuzumab was
generated by huminization of the murine
P67.6 clone, raised against CD33-transfected FMY9S5 cells of human
origin. CD33 is a transmembrane receptor expressed on predominantly on cells
of the myeloid lineage, but it can also be found on some lymphoid cells. |
IgG4 kappa |
| 24-283 |
CD33 Antibody
[hP67.6 (Gemtuzumab)], Rabbit IgG |
Gemtuzumab was
generated by huminization of the murine
P67.6 clone, raised against CD33-transfected FMY9S5 cells of human
origin. CD33 is a transmembrane receptor expressed on predominantly on cells
of the myeloid lineage, but it can also be found on some lymphoid cells. |
IgG kappa |
| 24-392 |
CD4 Antibody [CE9.1
(Clenoliximab)], Human IgG4 |
Domain 1 of human
CD4. |
IgG4 lambda |
| 24-393 |
CD4 Antibody [CE9.1
(Clenoliximab)], Rabbit IgG |
Domain 1 of human
CD4. |
IgG lambda |
| 24-386 |
CD40L Antibody
[hu5c8 (Ruplizumab)], Human IgG1 |
Human CD40L |
IgG1 kappa |
| 24-387 |
CD40L Antibody
[hu5c8 (Ruplizumab)], Rabbit IgG |
Human CD40L |
IgG kappa |
| 24-280 |
CD41 Antibody [7E3
(Abciximab)], Human IgG1 |
CD41 is the
integrin alpha chain 2b forming a fibrinogen receptor in heterodimeric
complex with beta 3. |
IgG1 kappa |
| 24-281 |
CD41 Antibody [7E3
(Abciximab)], Rabbit IgG |
CD41 is the
integrin alpha chain 2b forming a fibrinogen receptor in heterodimeric
complex with beta 3. |
IgG kappa |
| 24-499 |
CD80 Antibody
[IDEC-114 (Galiximab)], Human IgG1 |
Galiximab was
prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The
variable regions of the light and heavy chains were then cloned by being
incorporated into a cassette vector (N5LG1) containing human constant region
genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K,
2013) |
IgG1 lambda |
| 24-500 |
CD80 Antibody
[IDEC-114 (Galiximab)], Rabbit IgG |
Galiximab was
prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The
variable regions of the light and heavy chains were then cloned by being
incorporated into a cassette vector (N5LG1) containing human constant region
genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K,
2013) |
IgG lambda |
| 10-240 |
CDP571 (TNFSF2/TNF
alpha/TNFA) |
|
IgG4-kappa |
| 10-907 |
Cemiplimab
(PDCD1/PD1/CD279) |
Homo sapiens /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-946 |
Cendakimab (IL13) |
Humanized / IL13
[Homo sapiens] |
IgG1-kappa |
| 21-855 |
Certolizumab |
|
Fab-IgG1 |
| 10-891 |
Cetrelimab
(PDCD1/PD1/CD279) |
Homo sapiens /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-172 |
Cetuximab (EGFR) |
Chimeric / EGFR
[Homo sapiens] |
IgG1-kappa |
| 10-880 |
Cibisatamab
(CD3E/CEACAM5) |
Humanized /
CD3E/CEACAM5 [Homo sapiens] |
IgG1-kappa/lambda
with domain crossover |
| 21-870 |
Cilgavimab |
Humanized / RBD
[SARS-CoV-2] |
Human IgG |
| 21-893 |
Cilgavimab |
Homo sapiens /
SARS-CoV-2 Spike RBD |
IgG1，Kappa |
| 10-962 |
Cinpanemab (SNCA ) |
Humanized / SNCA
[Homo sapiens] |
IgG1-lambda |
| 10-258 |
Citatuzumab Bogatox
(EPCAM/CD326) |
Humanized /
EPCAM/CD326 [Homo sapiens] |
Fab-G1-kappa |
| 10-299 |
Cixutumumab
(IGF1R/CD221) |
Homo sapiens /
IGF1R/CD221 [Homo sapiens] |
IgG1-lambda |
| 10-486 |
Clazakizumab (IL6) |
Humanized / IL6
[Homo sapiens] |
IgG1-kappa |
| 10-173 |
Clenoliximab (CD4) |
Chimeric / CD4
[Homo sapiens] |
IgG4-lambda |
| 21-894 |
Clervonafusp |
Humanized / SLC29A2 |
IgG1，Kappa |
| 10-729 |
Clivatuzumab
Tetraxetan (MUC1/CD227) |
Humanized /
MUC1/CD227 [Homo sapiens] |
IgG1-kappa |
| 10-239 |
CMB-401
(MUC1/CD227) |
Homo sapiens /
MUC1/CD227 [Homo sapiens] |
IgG1-nd |
| 10-929 |
Cobolimab
(HAVCR2/TIM3/CD366) |
Humanized /
HAVCR2/TIM3/CD366 [Homo sapiens] |
IgG4-kappa |
| 10-597 |
Codrituzumab (GPC3) |
Humanized / GPC3
[Homo sapiens] |
IgG1-kappa |
| 10-859 |
Cofetuzumab (PTK7) |
Humanized / PTK7
[Homo sapiens] |
IgG1-kappa |
| 10-655 |
Coltuximab
Ravtansine (CD19 ) |
Chimeric / CD19
[Homo sapiens] |
IgG1-kappa |
| 10-245 |
Conatumumab
(TNFRSF10B/CD262) |
Homo sapiens /
TNFRSF10B/CD262 [Homo sapiens] |
IgG1-kappa |
| 10-578 |
Concizumab (TFPI) |
Humanized / TFPI
[Homo sapiens] |
IgG4-kappa |
| 21-895 |
Coprelotamab |
Humanized / ERBB2 |
IgG1，Kappa |
| 10-835 |
Cosfroviximab
(Zaire Ebola virus ) |
Chimeric / Zaire
Ebola virus [Zaire ebolavirus] |
IgG1-kappa |
| 10-975 |
Cosibelimab
(CD274/PD-L1/B7-H1) |
Homo sapiens /
CD274/PD-L1/B7-H1 [Homo sapiens] |
IgG1-lambda |
| 10-464 |
Crenezumab (APP
Abeta42 and Abeta40) |
Humanized / APP
Abeta42 and Abeta40 [Homo sapiens] |
IgG4-kappa |
| 10-808 |
Crizanlizumab
(SELP) |
Humanized / SELP
[Homo sapiens] |
IgG2-kappa |
| 10-760 |
Crotedumab (GCGR) |
Homo sapiens / GCGR
[Homo sapiens] |
IgG4-kappa |
| 10-871 |
Crovalimab (C5) |
Chimeric,Humanized
/ C5 [Homo sapiens] |
IgG1-kappa |
| 10-166 |
cT84.66
(CEACAM5/CD66e) |
Chimeric /
CEACAM5/CD66e [Homo sapiens] |
|
| 21-896 |
Cudarolimab |
Homo sapiens /
TNFRSF4 |
IgG1，Kappa |
| 10-877 |
Cusatuzumab
(CD70/TNFSF7) |
Humanized /
CD70/TNFSF7 [Homo sapiens] |
IgG1-lambda |
| 10-254 |
Dacetuzumab (CD40) |
Humanized / CD40
[Homo sapiens] |
IgG1-kappa |
| 10-069 |
Daclizumab (IL2RA) |
Humanized / IL2RA
[Homo sapiens] |
IgG1-kappa |
| 21-897 |
Dafsolimab |
Mus musculus / CD3E |
IgG2b,Kappa |
| 10-345 |
Dalotuzumab
(IGF1R/CD221) |
Humanized /
IGF1R/CD221 [Homo sapiens] |
IgG1-kappa |
| 10-631 |
Dapirolizumab
(CD40LG/CD154) |
Humanized /
CD40LG/CD154 [Homo sapiens] |
Fab'-G1-kappa |
| 10-316 |
Daratumumab (CD38) |
Homo sapiens / CD38
[Homo sapiens] |
IgG1-kappa |
| 21-898 |
Datopotamab |
Humanized / TACSTD2 |
IgG1，Kappa |
| 21-899 |
Daxdilimab |
Homo sapiens /
LILRA4 |
IgG1，Lambda |
| 10-688 |
Dectrekumab (IL13) |
Homo sapiens / IL13
[Homo sapiens] |
IgG1-kappa |
| 10-487 |
Demcizumab (DLL4 ) |
Humanized / DLL4
[Homo sapiens] |
IgG2-kappa |
| 21-900 |
Demupitamab |
Homo sapiens / EGFR |
IgG1，Kappa |
| 10-658 |
Denintuzumab
Mafodotin (CD19) |
Humanized / CD19
[Homo sapiens] |
IgG1-kappa |
| 10-267 |
Denosumab
(TNFSF11/CD254) |
Homo sapiens /
TNFSF11/CD254 [Homo sapiens] |
IgG2-kappa |
| 10-783 |
Depatuxizumab
(EGFR) |
Chimeric,Humanized
/ EGFR [Homo sapiens] |
IgG1-kappa |
| 21-901 |
Depemokimab |
Humanized / IL5 |
IgG1，Kappa |
| 10-791 |
Dezamizumab (APCS) |
Humanized / APCS
[Homo sapiens] |
IgG1-kappa |
| 10-908 |
Dilpacimab
(DLL4/VEGFA) |
Humanized /
DLL4/VEGFA [Homo sapiens] |
IgG1-kappa |
| 10-595 |
Dinutuximab
(ganglioside GD2) |
Chimeric /
ganglioside GD2 [Homo sapiens] |
IgG1-kappa |
| 10-659 |
Diridavumab
(influenza A virus hemagglutinin HA2 subunit from various strains) |
Homo sapiens /
influenza A virus hemagglutinin HA2 subunit from various strains [Influenza A
virus] |
IgG1-lambda |
| 10-963 |
Disitamab
(ERBB2/EGFR2/CD340) |
Humanized /
ERBB2/EGFR2/CD340 [Homo sapiens] |
IgG1-kappa |
| 21-902 |
Divozilimab |
Humanized / MS4A1 |
IgG1，Kappa |
| 21-903 |
Docaravimab |
Mus musculus /
Rabies Virus Strain ERA GP Ectodomain Epitope G-III |
IgG2b,Kappa |
| 10-774 |
Domagrozumab (MSTN
/GDF8) |
Humanized / MSTN
/GDF8 [Homo sapiens] |
IgG1-kappa |
| 21-904 |
Domvanalimab |
Humanized / TIGIT |
IgG1，Kappa |
| 10-934 |
Donanemab (APP) |
Humanized / APP
[Homo sapiens] |
IgG1-kappa |
| 10-909 |
Dostarlimab
(PDCD1/PD1/CD279) |
Humanized /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-349 |
Drozitumab
(TNFRSF10B/TRAILR2/CD262) |
Homo sapiens /
TNFRSF10B/TRAILR2/CD262 [Homo sapiens] |
IgG1-lambda |
| 10-488 |
Duligotuzumab
(ERBB3 ) |
Humanized / ERBB3
[Homo sapiens] |
IgG1-kappa |
| 10-580 |
Dupilumab
(IL4R/CD124) |
Homo sapiens /
IL4R/CD124 [Homo sapiens] |
IgG4-kappa |
| 10-680 |
Durvalumab
(CD274/B7-H1/PDL1) |
Homo sapiens /
CD274/B7-H1/PDL1 [Homo sapiens] |
IgG1-kappa |
| 10-582 |
Dusigitumab
(IGF1/IGF2) |
Homo sapiens /
IGF1/IGF2 [Homo sapiens] |
IgG2-nd |
| 10-780 |
Duvortuxizumab
(CD19/CD3E) |
Chimeric,Humanized
/ CD19/CD3E [Homo sapiens] |
scFv
-h-CH2-CH3(_scFv)_h-CH2-CH3 |
| 21-905 |
Ebdarokimab |
Humanized / IL12B |
IgG1，Kappa |
| 21-906 |
Ebronucimab |
Homo sapiens /
PCSK9 |
IgG1，Lambda |
| 10-288 |
Ecromeximab
(ganglioside GD4) |
Chimeric /
ganglioside GD4 [Homo sapiens] |
IgG1-kappa |
| 10-070 |
Eculizumab (C5) |
Humanized / C5
[Homo sapiens] |
IgG2-G4-kappa |
| 10-142 |
Edobacomab
(Endotoxin) |
Mus musculus /
Endotoxin [Gram negative bacteria] |
IgM-nd |
| 10-143 |
Edrecolomab (EPCAM) |
Mus musculus /
EPCAM [Homo sapiens] |
IgG2a-kappa |
| 10-194 |
Efungumab (HSP91
homolog) |
Homo sapiens /
HSP91 homolog [Candida albicans] |
scFv-heavy-kappa |
| 24-274 |
EGFR Antibody [C225
(Cetuximab)], Human IgG1 |
The epidermal
growth factor receptor is the
cell-surface receptor for members of the epidermal growth factor family
(EGF-family) of extracellular protein ligands. |
IgG1 kappa |
| 24-275 |
EGFR Antibody [C225
(Cetuximab)], Rabbit IgG |
The epidermal
growth factor receptor is the
cell-surface receptor for members of the epidermal growth factor family
(EGF-family) of extracellular protein ligands. |
IgG kappa |
| 24-425 |
EGFR Antibody
[Matuzumab], Human IgG1 |
The parental mouse
antibody was generated by immunizing BALB/c mice intraperitoneally with A431
cells in phosphate buffered saline (PBS).
Later on the humanzied version of the antibody was created by grafting
CDRs of the murine antibody onto human constant regions. |
IgG1 kappa |
| 24-426 |
EGFR Antibody
[Matuzumab], Rabbit IgG |
The parental mouse
antibody was generated by immunizing BALB/c mice intraperitoneally with A431
cells in phosphate buffered saline (PBS).
Later on the humanzied version of the antibody was created by grafting
CDRs of the murine antibody onto human constant regions. |
IgG kappa |
| 24-488 |
EGFR domain III
Antibody [h-R3 (Nimotuzumab)], Human IgG1 |
This antibody we
generated by humanisation of the murine antibody R3, raised against EGFR
purified from placenta membranes and A431 tumors. |
IgG1 kappa |
| 24-489 |
EGFR domain III
Antibody [h-R3 (Nimotuzumab)], Rabbit IgG |
This antibody we
generated by humanisation of the murine antibody R3, raised against EGFR
purified from placenta membranes and A431 tumors. |
IgG kappa |
| 10-594 |
Eldelumab (CXCL10) |
Homo sapiens /
CXCL10 [Homo sapiens] |
IgG1-kappa |
| 10-789 |
Elezanumab (RGMA) |
Homo sapiens / RGMA
[Homo sapiens] |
IgG1-lambda |
| 10-685 |
Elgemtumab (ERBB3) |
Homo sapiens /
ERBB3 [Homo sapiens] |
IgG1-kappa |
| 10-944 |
Elipovimab (HIV-1
gp120) |
Homo sapiens /
HIV-1 gp120 [Human immunodeficiency virus 1] |
IgG1-lambda |
| 10-307 |
Elotuzumab
(SLAMF7/CD319) |
Humanized /
SLAMF7/CD319 [Homo sapiens] |
IgG1-kappa |
| 10-283 |
Elsilimomab (IL6) |
Mus musculus / IL6
[Homo sapiens] |
IgG1-nd |
| 21-907 |
Eluvixtamab |
Humanized / CD33,
CD3E |
Bispecific
scFvKappa;Lambda |
| 10-666 |
Emactuzumab
(CSF1R/CD115) |
Humanized /
CSF1R/CD115 [Homo sapiens] |
IgG1-kappa |
| 10-806 |
Emapalumab (IFNG ) |
Homo sapiens / IFNG
[Homo sapiens] |
IgG1-lambda |
| 21-908 |
Emerfetamab |
Humanized / CD33,
CD3E |
Bispecific
scFv;Kappa;Lambda |
| 10-661 |
Emibetuzumab
(MET/RCCP2) |
Humanized /
MET/RCCP2 [Homo sapiens] |
IgG4-kappa |
| 10-733 |
Emicizumab
(F10/F9 activated form) |
Humanized / F10/F9
activated form [Homo sapiens] |
IgG4-kappa |
| 10-895 |
Enapotamab (AXL) |
Homo sapiens / AXL
[Homo sapiens] |
IgG1-kappa |
| 10-447 |
Enavatuzumab
(TNFRSF12A/CD266) |
Humanized /
TNFRSF12A/CD266 [Homo sapiens] |
IgG1-kappa |
| 10-977 |
Encelimab
(LAG3/CD223) |
Humanized /
LAG3/CD223 [Homo sapiens] |
IgG4-kappa |
| 10-625 |
Enfortumab Vedotin
(PVRL4) |
Homo sapiens /
PVRL4 [Homo sapiens] |
IgG1-kappa |
| 21-909 |
Enibarcimab |
Humanized / ADM |
IgG1，Kappa |
| 10-144 |
Enlimomab (ICAM1) |
Mus musculus /
ICAM1 [Homo sapiens] |
IgG2a-nd |
| 10-755 |
Enoblituzumab
(CD276/B7-H3) |
Humanized /
CD276/B7-H3 [Homo sapiens] |
IgG1-kappa |
| 10-448 |
Enokizumab (IL9) |
Humanized / IL9
[Homo sapiens] |
IgG1-kappa |
| 10-489 |
Enoticumab (DLL4 ) |
Homo sapiens / DLL4
[Homo sapiens] |
IgG1-kappa |
| 10-354 |
Ensituximab
(MUC5AC) |
Chimeric / MUC5AC
[Homo sapiens] |
IgG1-kappa |
| 10-964 |
Envafolimab
(CD274/PD-L1/B7-H1) |
Chimeric /
CD274/PD-L1/B7-H1 [Homo sapiens] |
(VH-CH2-CH3)2 |
| 10-978 |
Epcoritamab
(CD3E;MS4A1/CD20) |
Homo
sapiens,Chimeric / CD3E;MS4A1/CD20 [Homo sapiens] |
IgG4-kappa-lambda |
| 10-318 |
Epitumomab
(MUC1/CD227) |
Mus musculus /
MUC1/CD227 [Homo sapiens] |
IgG2a-nd |
| 10-073 |
Epratuzumab (CD22) |
Humanized / CD22
[Homo sapiens] |
IgG1-nd |
| 10-787 |
Eptinezumab (CALCA
/CALCB) |
Humanized / CALCA
/CALCB [Homo sapiens] |
IgG1-kappa |
| 24-087 |
erbB-2 (Her-2/neu)
Antibody [4D5-8 (trastuzumab)], Human IgG1 |
A431 cells (human
epidermoid carcinoma) (over)expressing EGFR. |
IgG1 kappa |
| 24-088 |
erbB-2 (Her-2/neu)
Antibody [4D5-8 (trastuzumab)], Rabbit IgG |
A431 cells (human
epidermoid carcinoma) (over)expressing EGFR. |
IgG kappa |
| 10-775 |
Erenumab
(CALCRL/CGRP-R) |
Homo sapiens /
CALCRL/CGRP-R [Homo sapiens] |
IgG2-lambda |
| 21-910 |
Erfonrilimab |
Humanized / CD274,
CTLA4 |
Bispecific Single
Domains (VH-VH'-CH),IgG1na;na |
| 10-292 |
Erlizumab
(ITGB2/CD18 ) |
Humanized /
ITGB2/CD18 [Homo sapiens] |
IgG1-nd |
| 10-243 |
Ertumaxomab
(CD3E/ERBB2/CD340) |
Mus musculus,Rattus
sp,Hybrid / CD3E/ERBB2/CD340 [Homo sapiens] |
IgG2a-kappa/G2b-lambda |
| 10-261 |
Etaracizumab
(ITGAV_ITGB3) |
Humanized /
ITGAV_ITGB3 [Homo sapiens] |
IgG1-nd |
| 21-880 |
Etesevimab |
Humanized / GP1
surface protein of Ebolavirus |
Human IgG1 |
| 21-911 |
Etesevimab |
Homo sapiens /
SARS-CoV-2 Spike RBD |
IgG1,Kappa |
| 10-885 |
Etigilimab
(TIGIT/VSTM3) |
Humanized /
TIGIT/VSTM3 [Homo sapiens] |
IgG1-kappa |
| 10-931 |
Etokimab (IL33) |
Humanized / IL33
[Homo sapiens] |
IgG1-kappa |
| 10-449 |
Etrolizumab
(ITGA4_ITGB7) |
Humanized /
ITGA4_ITGB7 [Homo sapiens] |
IgG1-kappa |
| 10-681 |
Evinacumab
(ANGPTL3) |
Homo sapiens /
ANGPTL3 [Homo sapiens] |
IgG4-kappa |
| 10-579 |
Evolocumab (PCSK9) |
Homo sapiens /
PCSK9 [Homo sapiens] |
IgG2-lambda |
| 10-279 |
Exbivirumab
(HBV/HBsAg) |
Homo sapiens /
HBV/HBsAg [Hepatitis B virus] |
IgG1-lambda |
| 21-912 |
Ezabenlimab |
Humanized / PDCD1 |
IgG4,Kappa |
| 10-320 |
Faralimomab (IFNA1) |
Mus musculus /
IFNA1 [Homo sapiens] |
IgG1-nd |
| 10-878 |
Faricimab
(ANGPT2/VEGFA) |
Homo
sapiens,Humanized / ANGPT2/VEGFA [Homo sapiens] |
IgG1-kappa-lambda |
| 10-308 |
Farletuzumab (FOLR1
) |
Humanized / FOLR1
[Homo sapiens] |
IgG1-kappa |
| 10-490 |
Fasinumab (NGF/NGFB
) |
Homo sapiens /
NGF/NGFB [Homo sapiens] |
IgG4-kappa |
| 21-913 |
Feladilimab |
Humanized / ICOS |
IgG4,Kappa |
| 10-099 |
Felvizumab (RSV) |
Humanized / RSV
[Respiratory syncytial virus] |
IgG1-kappa |
| 10-336 |
Fezakinumab (IL22) |
Homo sapiens / IL22
[Homo sapiens] |
IgG1-lambda |
| 10-979 |
Fianlimab
(LAG3/CD223) |
Homo sapiens /
LAG3/CD223 [Homo sapiens] |
IgG4-kappa |
| 10-465 |
Ficlatuzumab (HGF) |
Humanized / HGF
[Homo sapiens] |
IgG1-kappa |
| 10-309 |
Figitumumab
(IGF1R/CD221) |
Homo sapiens /
IGF1R/CD221 [Homo sapiens] |
IgG2-kappa |
| 21-914 |
Finotonlimab |
Humanized / PDCD1 |
IgG4,Kappa |
| 10-671 |
Firivumab
(Influenza A virus hemagglutinin HA) |
Homo sapiens /
Influenza A virus hemagglutinin HA [Influenza A virus] |
IgG1-kappa |
| 10-478 |
Flanvotumab (TYRP1) |
Homo sapiens /
TYRP1 [Homo sapiens] |
IgG1-kappa |
| 10-630 |
Fletikumab (IL20 ) |
Homo sapiens / IL20
[Homo sapiens] |
IgG4-kappa |
| 10-818 |
Flotetuzumab
(CD3E/IL3RA/CD123) |
Mus
musculus;Humanized / CD3E/IL3RA/CD123 [Homo sapiens] |
VH-VL-VH'-VL' |
| 10-074 |
Fontolizumab (IFNG) |
Humanized / IFNG
[Homo sapiens] |
IgG1-nd |
| 10-437 |
Foralumab (CD3E) |
Homo sapiens / CD3E
[Homo sapiens] |
IgG1-kappa |
| 10-125 |
Foravirumab (RV) |
Homo sapiens / RV
[Rabies virus] |
IgG1-kappa |
| 10-785 |
Fremanezumab (CALCA
/CALCB) |
Humanized / CALCA
/CALCB [Homo sapiens] |
IgG2-kappa |
| 10-195 |
Fresolimumab
(TGFB/TGF beta) |
Homo sapiens /
TGFB/TGF beta [Homo sapiens] |
IgG4-kappa |
| 10-910 |
Frovocimab (PCSK9) |
Humanized / PCSK9
[Homo sapiens] |
IgG4-kappa |
| 10-824 |
Frunevetmab
(NGF/NGFB) |
Felinized /
NGF/NGFB [Mus musculus] |
IgG1-kappa |
| 10-450 |
Fulranumab
(NGF/NGFB) |
Homo sapiens /
NGF/NGFB [Homo sapiens] |
IgG2-kappa |
| 10-491 |
Futuximab
(EGFR domain III /ERBB1) |
Chimeric / EGFR
domain III /ERBB1 [Homo sapiens] |
IgG1-kappa |
| 10-773 |
Galcanezumab
(CALCA/CGRP1/CALCB/CGRP2) |
Humanized /
CALCA/CGRP1/CALCB/CGRP2 [Homo sapiens] |
IgG4-kappa |
| 10-175 |
Galiximab (CD80
(B7-1,CD28LG2)) |
Chimeric / CD80
(B7-1,CD28LG2) [Homo sapiens] |
IgG1-lambda |
| 10-925 |
Gancotamab
(ERBB2/EGFR2/CD340) |
Homo sapiens /
ERBB2/EGFR2/CD340 [Homo sapiens] |
scFv-heavy-lambda |
| 10-189 |
Ganitumab
(IGF1R/CD221) |
Homo sapiens /
IGF1R/CD221 [Homo sapiens] |
IgG1-kappa |
| 10-244 |
Gantenerumab (APP
/Abeta42/Abeta40) |
Homo sapiens / APP
/Abeta42/Abeta40 [Homo sapiens] |
IgG1-kappa |
| 10-949 |
Garadacimab (F12) |
Humanized / F12
[Homo sapiens] |
IgG4-lambda |
| 10-817 |
Garetosmab (INHBA) |
Humanized / INHBA
[Homo sapiens] |
IgG4-kappa |
| 21-915 |
Garivulimab |
Humanized / CD274 |
IgG1，Kappa |
| 10-842 |
Gatipotuzumab
(MUC1/CD227) |
Humanized /
MUC1/CD227 [Homo sapiens] |
IgG1-kappa |
| 10-980 |
Gatralimab (CD52) |
Chimeric,Humanized
/ CD52 [Homo sapiens] |
IgG1-kappa |
| 10-828 |
Gedivumab
(Influenza A virus hemagglutinin HA) |
Homo sapiens /
Influenza A virus hemagglutinin HA [Influenza A virus] |
IgG1-kappa |
| 10-081 |
Gemtuzumab (CD33) |
Humanized / CD33
[Homo sapiens] |
IgG4-kappa |
| 21-916 |
Geptanolimab |
Humanized / PDCD1 |
IgG4,Kappa |
| 10-129 |
Gevokizumab (IL1B) |
Humanized / IL1B
[Homo sapiens] |
IgG2-kappa |
| 10-834 |
Gilvetmab
(PDCD1/PD1/CD279) |
Caninized /
PDCD1/PD1/CD279 [Canis lupus familiaris] |
IgG2-kappa |
| 10-847 |
Gimsilumab (CSF2
/GM-CSF) |
Homo sapiens / CSF2
/GM-CSF [Homo sapiens] |
IgG1-kappa |
| 10-341 |
Girentuximab (CA9) |
Chimeric / CA9
[Homo sapiens] |
IgG1-kappa |
| 10-344 |
Glembatumumab
(GPNMB extracellular domain) |
Homo sapiens /
GPNMB extracellular domain [Homo sapiens] |
IgG2-kappa |
| 10-938 |
Glenzocimab (GP6) |
Humanized / GP6
[Homo sapiens] |
Fab-G1-kappa |
| 10-981 |
Glofitamab
(CD3E/MS4A1) |
Humanized /
CD3E/MS4A1 [Homo sapiens] |
IgG1-kappa-lambda |
| 10-196 |
Golimumab (TNFA/TNF
alpha) |
Homo sapiens /
TNFA/TNF alpha [Homo sapiens] |
IgG1-kappa |
| 21-917 |
Gomiliximab |
|
IgG1，Kappa |
| 10-911 |
Gosuranemab (MAPT) |
Chimeric / MAPT
[Homo sapiens] |
IgG4-kappa |
| 10-982 |
Gremubamab (PcrV) |
Homo
sapiens,Humanized / PcrV [Bradyrhizobium sp.ANU 289,Gram negative bacteria] |
VH-CH1-VH-V-KAPPA-CH2-CH3 |
| 21-918 |
Grisnilimab |
Mus musculus / CD7 |
IgG2a,Lambda |
| 10-599 |
Guselkumab (IL23A) |
Homo sapiens /
IL23A [Homo sapiens] |
IgG1-lambda |
| 10-136 |
Huj591-Gsmab
(FOLH1/PSMA) |
Mus musculus /
FOLH1/PSMA [Homo sapiens] |
|
| 24-375 |
Human Muscle
Acetylcholine Receptor Antibody [mAb 192], Rat IgG2b |
Human muscle AChR. |
IgG2b kappa |
| 10-198 |
Humax-Il15 (IL15) |
Homo sapiens / IL15
[Homo sapiens] |
IgG1-kappa |
| 10-849 |
Ianalumab
(TNFRSF13C/CD268) |
Homo sapiens /
TNFRSF13C/CD268 [Homo sapiens] |
IgG1-kappa |
| 10-262 |
Ibalizumab (CD4 D3
domain) |
Humanized / CD4 D3
domain [Homo sapiens] |
IgG4-kappa |
| 21-856 |
Ibritumomab |
Humanized / MS4A1
(CD20, MS4A-1) [Homo sapiens] |
Human IgG2A |
| 10-176 |
ICM3 (CD50) |
Chimeric,Humanized
/ CD50 [Homo sapiens] |
|
| 10-451 |
Icrucumab (FLT1/
VEGFR-1) |
Homo sapiens /
FLT1/ VEGFR-1 [Homo sapiens] |
IgG1-kappa |
| 21-919 |
Idactamab |
Homo sapiens /
SLC1A5 |
IgG1，Kappa |
| 10-593 |
Idarucizumab
(dabigatran etexilate mesylate) |
Humanized /
dabigatran etexilate mesylate [Drug] |
Fab-G1-kappa |
| 10-951 |
Ieramilimab (LAG3 ) |
Humanized / LAG3
[Homo sapiens] |
IgG4-kappa |
| 10-740 |
Ifabotuzumab
(EPHA3/REK4) |
Humanized /
EPHA3/REK4 [Homo sapiens] |
IgG1-kappa |
| 24-241 |
IL-2R alpha (CD25)
Antibody [Basiliximab], Human IgG1 |
Basiliximab was
prepared by immunizing BALB/c mice with CTC 16 cells. |
IgG1 kappa |
| 24-242 |
IL-2R alpha (CD25)
Antibody [Basiliximab], Rabbit IgG |
Basiliximab was
prepared by immunizing BALB/c mice with CTC 16 cells. |
IgG kappa |
| 24-239 |
IL-2R Antibody
[Daclizumab], Human IgG1 |
Cultured T-cells
derived from a patient with Mycosis fungoides. |
IgG1 kappa |
| 24-240 |
IL-2R Antibody
[Daclizumab], Rabbit IgG |
Cultured T-cells
derived from a patient with Mycosis fungoides. |
IgG kappa |
| 24-501 |
IL-6 receptor
Antibody [rhPM-1 (Tocilizumab)], Human IgG1 |
The original
antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI
and NEW framework regions to create rhPM-1. |
IgG1 kappa |
| 24-502 |
IL-6 receptor
Antibody [rhPM-1 (Tocilizumab)], Rabbit IgG |
The original
antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI
and NEW framework regions to create rhPM-1. |
IgG kappa |
| 10-857 |
Iladatuzumab
(CD79B) |
Humanized / CD79B
[Homo sapiens] |
IgG1-kappa |
| 10-669 |
Imalumab (MIF) |
Homo sapiens / MIF
[Homo sapiens] |
IgG1-kappa |
| 10-890 |
Imaprelimab (MCAM) |
Humanized / MCAM
[Homo sapiens] |
IgG1-kappa |
| 10-199 |
IMC-1C11 (VEGFA) |
Chimeric / VEGFA
[Homo sapiens] |
|
| 21-920 |
Imdevimab |
Homo sapiens /
SARS-CoV-2 Spike RBD |
IgG1，Lambda |
| 10-492 |
Imgatuzumab (EGFR ) |
Humanized / EGFR
[Homo sapiens] |
IgG1-kappa |
| 21-921 |
Imsidolimab |
Humanized / IL36R |
IgG4,Kappa |
| 10-477 |
Inclacumab (SELP) |
Homo sapiens / SELP
[Homo sapiens] |
IgG4-kappa |
| 10-474 |
Indatuximab
Ravtansine (SDC1/CD138) |
Chimeric /
SDC1/CD138 [Homo sapiens] |
IgG4-kappa |
| 10-693 |
Indusatumab
(GUCY2C) |
Homo sapiens /
GUCY2C [Homo sapiens] |
IgG1-kappa |
| 10-700 |
Inebilizumab (CD19) |
Humanized / CD19
[Homo sapiens] |
IgG1-kappa |
| 10-177 |
Infliximab
(TNF-alpha) |
Chimeric /
TNF-alpha [Homo sapiens] |
IgG1-kappa |
| 10-150 |
Inolimomab (IL2RA) |
Mus musculus /
IL2RA [Homo sapiens] |
IgG1-kappa |
| 10-276 |
Inotuzumab
Ozogamicin (CD22) |
Humanized / CD22
[Homo sapiens] |
IgG4-kappa |
| 24-484 |
Integrin alpha 4
Antibody [Natalizumab], Human IgG4 |
The RAMOS cell
line, a non-EBV releasing cell line, injected into mice. |
IgG4 kappa |
| 24-485 |
Integrin alpha 4
Antibody [Natalizumab], Rabbit IgG |
The RAMOS cell
line, a non-EBV releasing cell line, injected into mice. |
IgG kappa |
| 10-334 |
Intetumumab
(ITGAV_ITGB3) |
Homo sapiens /
ITGAV_ITGB3 [Homo sapiens] |
IgG1-kappa |
| 10-779 |
Iodine (131I)
Apamistamab (PTPRC/CD45) |
Mus musculus /
PTPRC/CD45 [Homo sapiens] |
IgG1-kappa |
| 10-165 |
Iodine (131I)
Derlotuximab Biotin (DNA/histone(H1) complex) |
Chimeric /
DNA/histone(H1) complex [Homo sapiens] |
IgG1-kappa |
| 10-214 |
Ipilimumab
(CTLA4/CD152) |
Homo sapiens /
CTLA4/CD152 [Homo sapiens] |
IgG1-kappa |
| 10-268 |
Iratumumab
(TNFRSF8/CD30) |
Homo sapiens /
TNFRSF8/CD30 [Homo sapiens] |
IgG1-kappa |
| 10-690 |
Isatuximab (CD38) |
Chimeric / CD38
[Homo sapiens] |
IgG1-kappa |
| 10-881 |
Iscalimab
(CD40/TNFRSF5) |
Homo sapiens /
CD40/TNFRSF5 [Homo sapiens] |
IgG1-kappa |
| 10-695 |
Istiratumab
(ERBB3/IGF1R/CD221) |
Homo sapiens /
ERBB3/IGF1R/CD221 [Homo sapiens] |
IgG1-kappa -[scFv]2 |
| 10-438 |
Itolizumab (CD6) |
Humanized / CD6
[Homo sapiens] |
IgG1-kappa |
| 10-983 |
Ivuxolimab
(TNFRSF4/CD134) |
Homo sapiens /
TNFRSF4/CD134 [Homo sapiens] |
IgG2-kappa |
| 10-466 |
Ixekizumab (IL17A ) |
Humanized / IL17A
[Homo sapiens] |
IgG4-kappa |
| 21-922 |
Izuralimab |
Humanized / ICOS,
PDCD1 |
Bispecific Mixed
mAb and scFv IgG1;na,Kappa;Kappa |
| 10-215 |
J695 (IL12A/CD18) |
Homo
sapiens,Humanized / IL12A/CD18 [Homo sapiens] |
IgG-nd |
| 10-178 |
Keliximab (CD4) |
Chimeric / CD4
[Homo sapiens] |
IgG1-lambda |
| 10-085 |
Labetuzumab
(CEACAM5) |
Humanized / CEACAM5
[Homo sapiens] |
IgG-nd |
| 10-833 |
Lacnotuzumab
(CSF1/MCSF) |
Humanized /
CSF1/MCSF [Homo sapiens] |
IgG1-kappa |
| 10-675 |
Lacutamab (KIR3DL2) |
Chimeric,Humanized
/ KIR3DL2 [Homo sapiens] |
IgG1-kappa |
| 10-853 |
Ladiratuzumab
(SLC39A6) |
Humanized / SLC39A6
[Homo sapiens] |
IgG1-kappa |
| 10-493 |
Lampalizumab (CFD) |
Humanized / CFD
[Homo sapiens] |
Fab-G1-kappa |
| 10-771 |
Lanadelumab (KLKB1) |
Homo sapiens /
KLKB1 [Homo sapiens] |
IgG1-kappa |
| 10-746 |
Landogrozumab
(MSTN/GDF8) |
Humanized /
MSTN/GDF8 [Homo sapiens] |
IgG4-kappa |
| 10-765 |
Laprituximab (EGFR) |
Chimeric / EGFR
[Homo sapiens] |
IgG1-kappa |
| 10-837 |
Larcaviximab (Zaire
Ebola virus) |
Chimeric / Zaire
Ebola virus [Zaire ebolavirus] |
IgG1-kappa |
| 21-923 |
Latozinemab |
Homo sapiens /
SORT1 |
IgG1，Kappa |
| 10-338 |
Lebrikizumab (IL13) |
Humanized / IL13
[Homo sapiens] |
IgG4-kappa |
| 10-293 |
Lemalesomab (NCA-90
) |
Mus musculus /
NCA-90 [Homo sapiens] |
IgG1-nd |
| 21-924 |
Lemzoparlimab |
Humanized / CD47 |
IgG4,Kappa |
| 10-887 |
Lenvervimab (HBV) |
Humanized / HBV
[Homo sapiens] |
IgG1-kappa |
| 10-670 |
Lenzilumab (CSF2) |
Homo sapiens / CSF2
[Homo sapiens] |
IgG1-kappa |
| 10-216 |
Lerdelimumab
(TGFB2) |
Homo sapiens /
TGFB2 [Homo sapiens] |
IgG4-nd |
| 10-889 |
Leronlimab
(CCR5/CD195) |
Humanized /
CCR5/CD195 [Homo sapiens] |
IgG4-kappa |
| 10-825 |
Lesofavumab
(Influenza B virus hemagglutinin) |
Homo sapiens /
Influenza B virus hemagglutinin [Influenza B virus] |
IgG1-kappa |
| 21-925 |
Letaplimab |
Homo sapiens / CD47 |
IgG4,Kappa |
| 10-822 |
Letolizumab
(CD40LG/CD154) |
Humanized /
CD40LG/CD154 [Homo sapiens] |
(VH-CH2-CH3)2 |
| 10-930 |
Levilimab (IL6R) |
Chimeric,Humanized
/ IL6R [Homo sapiens] |
IgG1-kappa |
| 10-217 |
Lexatumumab
(TNFRSF10B/CD262) |
Homo sapiens /
TNFRSF10B/CD262 [Homo sapiens] |
IgG1-lambda |
| 10-280 |
Libivirumab
(HBV/HBsAg) |
Homo sapiens /
HBV/HBsAg [Hepatitis B virus] |
IgG1-kappa |
| 21-926 |
Licaminlimab |
Humanized / TNFA |
Lambda |
| 10-628 |
Lifastuzumab
Vedotin (SLC34A2) |
Humanized / SLC34A2
[Homo sapiens] |
IgG1-kappa |
| 10-494 |
Ligelizumab (IGHE) |
Humanized / IGHE
[Homo sapiens] |
IgG1-kappa |
| 10-691 |
Lilotomab (CD37) |
Mus musculus / CD37
[Homo sapiens] |
IgG1-kappa |
| 10-083 |
Lintuzumab (CD33) |
Humanized / CD33
[Homo sapiens] |
IgG1-kappa |
| 10-495 |
Lirilumab (KIRD2
subgroup) |
Homo sapiens /
KIRD2 subgroup [Homo sapiens] |
IgG4-kappa |
| 10-984 |
Lodapolimab
(PDCD1/PD-1/CD279) |
Homo sapiens /
PDCD1/PD-1/CD279 [Homo sapiens] |
IgG1-lambda |
| 10-592 |
Lodelcizumab
(PCSK9) |
Humanized / PCSK9
[Homo sapiens] |
IgG1-kappa |
| 10-679 |
Lokivetmab (IL31) |
Caninized / IL31
[Canis lupus familiaris] |
IgG2-kappa |
| 10-850 |
Loncastuximab (CD19
) |
Chimeric / CD19
[Homo sapiens] |
IgG1-kappa |
| 21-927 |
Lonigutamab |
Humanized / IGF1R |
IgG1，Kappa |
| 21-928 |
Lorukafusp |
Chimeric /
Ganglioside GD2 |
IgG1，Kappa |
| 10-084 |
Lorvotuzumab
Mertansine (NCAM1/CD56) |
Humanized /
NCAM1/CD56 [Homo sapiens] |
IgG1-kappa |
| 10-820 |
Losatuxizumab
(EGFR) |
Chimeric,Humanized
/ EGFR [Homo sapiens] |
IgG1-kappa |
| 10-197 |
Lucatumumab (CD40) |
Homo sapiens / CD40
[Homo sapiens] |
IgG1-kappa |
| 10-664 |
Lulizumab (CD28 ) |
Humanized / CD28
[Homo sapiens] |
V-kappa |
| 10-179 |
Lumiliximab (FCER2) |
Chimeric / FCER2
[Homo sapiens] |
IgG1-kappa |
| 10-667 |
Lumretuzumab
(ERBB3) |
Humanized / ERBB3
[Homo sapiens] |
IgG1-kappa |
| 10-782 |
Lupartumab (LYPD3) |
Homo sapiens /
LYPD3 [Homo sapiens] |
IgG1-lambda |
| 21-929 |
Lusvertikimab |
Humanized / IL7R |
IgG4,Kappa |
| 10-790 |
Lutikizumab (IL1A
/IL1B) |
Humanized / IL1A
/IL1B [Homo sapiens] |
[VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer |
| 10-816 |
Maftivimab (Zaire
Ebola virus) |
Homo sapiens /
Zaire Ebola virus [Zaire ebolavirus] |
IgG1-kappa |
| 10-950 |
Magrolimab (CD47 ) |
Chimeric,Humanized
/ CD47 [Homo sapiens] |
IgG4-kappa |
| 10-985 |
Manelimab
(CD274/PD-L1/B7-H1) |
Homo sapiens /
CD274/PD-L1/B7-H1 [Homo sapiens] |
IgG1-lambda |
| 10-218 |
Mapatumumab
(TNFRSF10A/CD261) |
Homo sapiens /
TNFRSF10A/CD261 [Homo sapiens] |
IgG1-nd |
| 10-616 |
Margetuximab
(ERBB2/EGFR2/CD340) |
Chimeric /
ERBB2/EGFR2/CD340 [Homo sapiens] |
IgG1-kappa |
| 10-912 |
Marstacimab (TFPI) |
Homo sapiens / TFPI
[Homo sapiens] |
IgG1-lambda |
| 10-332 |
Maslimomab (T cell
receptor) |
Mus musculus / T
cell receptor [Homo sapiens] |
IgG2b-nd |
| 10-072 |
Matuzumab (EGFR) |
Humanized / EGFR
[Homo sapiens] |
IgG1-nd |
| 10-986 |
Mavezelimab
(LAG3/CD223) |
Humanized /
LAG3/CD223 [Homo sapiens] |
IgG4-kappa |
| 10-347 |
Mavrilimumab
(CSF2RA/CD116 ) |
Homo sapiens /
CSF2RA/CD116 [Homo sapiens] |
IgG4-lambda2 |
| 21-930 |
Melrilimab |
Homo sapiens /
IL1RL1 |
IgG2,Kappa |
| 21-853 |
Meplazumab |
Humanized / CD147
[Homo sapiens] |
IgG1-kappa |
| 10-123 |
Mepolizumab (IL5) |
Humanized / IL5
[Homo sapiens] |
IgG1-kappa |
| 10-221 |
Metelimumab (TGFB1) |
Homo sapiens /
TGFB1 [Homo sapiens] |
IgG4-kappa |
| 10-928 |
Mezagitamab (CD38 ) |
Humanized / CD38
[Homo sapiens] |
IgG1-lambda |
| 21-931 |
Mibavademab |
Humanized / LEPR |
IgG4,Kappa |
| 10-158 |
Milatuzumab (CD74) |
Humanized / CD74
[Homo sapiens] |
IgG1-kappa |
| 10-324 |
Minretumomab
(TAG-72) |
Mus musculus /
TAG-72 [Homo sapiens] |
IgG1-nd |
| 21-932 |
Mipasetamab |
Humanized / AXL |
IgG1，Kappa |
| 21-933 |
Miptenalimab |
Humanized / LAG3 |
IgG4,Kappa |
| 10-858 |
Mirikizumab (IL23A) |
Humanized / IL23A
[Homo sapiens] |
IgG4-kappa |
| 21-934 |
Miromavimab |
Mus musculus /
Rabies Virus Strain ERA GP Ectodomain Epitope G-II |
IgG1,Kappa |
| 10-757 |
Mirvetuximab
(FOLR1) |
Chimeric / FOLR1
[Homo sapiens] |
IgG1-kappa |
| 10-987 |
Mirzotamab
(CD276/B7-H3) |
Chimeric,Humanized
/ CD276/B7-H3 [Homo sapiens] |
IgG1-kappa |
| 10-893 |
Mitazalimab
(CD40/TNFRSF5) |
Humanized /
CD40/TNFRSF5 [Homo sapiens] |
IgG1-lambda |
| 10-187 |
Mk-4721 (PSCA) |
Homo sapiens / PSCA
[Homo sapiens] |
IgG1-kappa |
| 21-935 |
Modakafusp |
Humanized / ADPRC |
IgG4,Kappa |
| 10-577 |
Modotuximab
(EGFR/ERBB1 domain III) |
Chimeric /
EGFR/ERBB1 domain III [Homo sapiens] |
IgG1-kappa |
| 10-452 |
Mogamulizumab
(CCR4/CD194) |
Humanized /
CCR4/CD194 [Homo sapiens] |
IgG1-kappa |
| 10-731 |
Monalizumab
(KLRC1/NKG2A/CD159a/CD94) |
Humanized /
KLRC1/NKG2A/CD159a/CD94 [Homo sapiens] |
IgG4-kappa |
| 10-223 |
MOR101 (ICAM1/CD54) |
Homo sapiens /
ICAM1/CD54 [Homo sapiens] |
Fab-nd-nd |
| 10-224 |
MOR102 (ICAM1/CD54) |
Homo sapiens /
ICAM1/CD54 [Homo sapiens] |
Fab-G4-nd |
| 10-226 |
MOR202 (CD38) |
Homo sapiens / CD38
[Homo sapiens] |
IgG1-nd |
| 10-326 |
Morolimumab
(RHD/CD240D) |
Homo sapiens /
RHD/CD240D [Homo sapiens] |
IgG1-nd |
| 10-851 |
Mosunetuzumab
(CD3E/MS4A1/CD20) |
Humanized /
CD3E/MS4A1/CD20 [Homo sapiens] |
IgG1-kappa |
| 10-089 |
Motavizumab (RSV) |
Humanized / RSV
[Respiratory syncytial virus] |
IgG1-kappa |
| 21-866 |
Moxetumomab |
|
|
| 10-904 |
Murlentamab (AMHR2) |
Humanized / AMHR2
[Homo sapiens] |
IgG1-kappa |
| 10-155 |
Muromonab-Cd3
(CD3E) |
Mus musculus / CD3E
[Homo sapiens] |
IgG2a-kappa |
| 10-330 |
Nacolomab Tafenatox
(MUC1 sialylated CA242) |
Mus musculus / MUC1
sialylated CA242 [Homo sapiens] |
Fab-G1-kappa |
| 21-936 |
Nadecnemab |
Homo sapiens /
GFRA3 |
IgG4,Kappa |
| 10-453 |
Namilumab
(CSF2/GM-CSF) |
Homo sapiens /
CSF2/GM-CSF [Homo sapiens] |
IgG1-kappa |
| 10-087 |
Naptumomab
Estafenatox (TPBG) |
Mus musculus / TPBG
[Homo sapiens] |
Fab-G1-kappa |
| 10-767 |
Naratuximab
(CD37/TSPAN26) |
Chimeric /
CD37/TSPAN26 [Homo sapiens] |
IgG1-kappa |
| 10-467 |
Narnatumab
(MST1R/CD136) |
Homo sapiens /
MST1R/CD136 [Homo sapiens] |
IgG1-kappa |
| 10-869 |
Narsoplimab (MASP2) |
Homo sapiens /
MASP2 [Homo sapiens] |
IgG4-lambda |
| 10-090 |
Natalizumab
(ITGA4/CD49d) |
Humanized /
ITGA4/CD49d [Homo sapiens] |
IgG4-kappa |
| 10-762 |
Navicixizumab
(DLL4/VEGFA) |
Chimeric,Humanized
/ DLL4/VEGFA [Homo sapiens] |
IgG2-kappa |
| 10-698 |
Navivumab
(Influenza A virus hemagglutinin HA) |
Homo sapiens /
Influenza A virus hemagglutinin HA [Influenza A virus] |
IgG1-kappa |
| 10-932 |
Naxitamab
(Ganglioside GD2) |
Chimeric /
Ganglioside GD2 [Homo sapiens] |
IgG1-kappa |
| 10-229 |
Nebacumab
(Endotoxin) |
Homo sapiens /
Endotoxin [Gram negative bacteria] |
IgM-kappa |
| 10-310 |
Necitumumab
(EGFR/ERBB1 ) |
Homo sapiens /
EGFR/ERBB1 [Homo sapiens] |
IgG1-kappa |
| 10-689 |
Nemolizumab
(IL31RA) |
Humanized / IL31RA
[Homo sapiens] |
IgG2-kappa |
| 10-583 |
Nesvacumab (ANGPT2) |
Homo sapiens /
ANGPT2 [Homo sapiens] |
IgG1-nd |
| 10-876 |
Netakimab (IL17A) |
Homo
sapiens,Chimeric / IL17A [Homo sapiens] |
IgG1-kappa |
| 10-960 |
Nidanilimab
(IL1RAP) |
Humanized / IL1RAP
[Homo sapiens] |
IgG1-kappa |
| 10-955 |
Nimacimab (CNR1) |
Humanized / CNR1
[Homo sapiens] |
IgG4-kappa |
| 10-091 |
Nimotuzumab (EGFR) |
Humanized / EGFR
[Homo sapiens] |
IgG1-kappa |
| 21-937 |
Nipocalimab |
Homo sapiens /
FCGRT |
IgG1,Lambda |
| 10-913 |
Nirsevimab (RSV) |
Humanized / RSV
[Homo sapiens] |
IgG1-kappa |
| 21-938 |
Nivatrotamab |
Humanized / GD2,
CD3E |
Bispecific Mixed
mAb and scFv IgG1;naKappa;Kappa |
| 10-496 |
Nivolumab
(PDCD1/PD1/CD279) |
Homo sapiens /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-989 |
Nurulimab (CTLA4) |
Homo sapiens /
CTLA4 [Homo sapiens] |
IgG1-kappa |
| 10-674 |
Obexelimab (CD19) |
Chimeric / CD19
[Homo sapiens] |
IgG1-kappa |
| 10-697 |
Obiltoxaximab
(Anthrax protective antigen) |
Chimeric / Anthrax
protective antigen [Bacillus anthracis] |
IgG1-kappa |
| 10-260 |
Obinutuzumab
(MS4A1/CD20) |
Humanized /
MS4A1/CD20 [Homo sapiens] |
IgG1-kappa |
| 21-939 |
Obrindatamab |
Humanized / CD276,
CD3E |
Bispecific scFv
with Domain Crossover,Kappa;Lambda |
| 10-497 |
Ocaratuzumab
(MS4A1/CD20) |
Humanized /
MS4A1/CD20 [Homo sapiens] |
IgG1-kappa |
| 21-940 |
Ociperlimab |
Humanized / TIGIT |
IgG1,Kappa |
| 10-249 |
Ocrelizumab
(MS4A1/CD20) |
Humanized /
MS4A1/CD20 [Homo sapiens] |
IgG1-nd |
| 10-990 |
Odesivimab (Zaire
Ebola virus) |
Homo sapiens /
Zaire Ebola virus [Zaire ebolavirus] |
IgG1-kappa |
| 10-991 |
Odronextamab (CD3E) |
Homo sapiens / CD3E
[Homo sapiens] |
IgG4-kappa |
| 10-157 |
Odulimomab
(ITGAL/CD11a) |
Mus musculus /
ITGAL/CD11a [Homo sapiens] |
F(ab')2-G1-nd |
| 10-230 |
Ofatumumab
(MS4A1/CD20) |
Homo sapiens /
MS4A1/CD20 [Homo sapiens] |
IgG1-kappa |
| 10-439 |
Olaratumab
(PDGFRA/PDGFR2/CD140a) |
Homo sapiens /
PDGFRA/PDGFR2/CD140a [Homo sapiens] |
IgG1-kappa |
| 10-838 |
Oleclumab
(NT5E/CD37) |
Homo sapiens /
NT5E/CD37 [Homo sapiens] |
IgG1-lambda |
| 11-052 |
Olendalizumab (C5) |
Humanized / C5
[Homo sapiens] |
IgG2-G4-kappa |
| 10-902 |
Olinvacimab
(KDR/VEGFR2) |
Humanized /
KDR/VEGFR2 [Homo sapiens] |
IgG1-kappa-lambda |
| 10-440 |
Olokizumab (IL6) |
Humanized / IL6
[Homo sapiens] |
IgG4-kappa |
| 10-092 |
Omalizumab (IGHE) |
Humanized / IGHE
[Homo sapiens] |
IgG1-kappa |
| 10-915 |
Omburtamab
(CD276/B7-H3/B7RP-2) |
Mus musculus /
CD276/B7-H3/B7RP-2 [Homo sapiens] |
IgG1-kappa |
| 21-941 |
Omodenbamab |
Homo sapiens / SpA |
IgG3,Kappa |
| 10-454 |
Onartuzumab
(MET/RCCP2) |
Humanized /
MET/RCCP2 [Homo sapiens] |
Fab-G1-kappa
-[Fc-G1] |
| 10-180 |
Oncolym (HLA-DR10) |
Mus musculus /
HLA-DR10 [Homo sapiens] |
IgG2a-nd |
| 21-942 |
Onfekafusp |
Homo sapiens / FN
extra domain B |
Kappa |
| 21-943 |
Ongericimab |
Humanized / PCSK9 |
IgG4,Kappa |
| 10-873 |
Ontamalimab
(MADCAM1) |
Homo sapiens /
MADCAM1 [Homo sapiens] |
IgG2-kappa |
| 10-656 |
Ontuxizumab (CD248) |
Chimeric,Humanized
/ CD248 [Homo sapiens] |
IgG1-kappa |
| 10-892 |
Onvatilimab (VSIR) |
Homo sapiens / VSIR
[Homo sapiens] |
IgG1-kappa |
| 10-726 |
Opicinumab
(LINGO1/LRRN6A/LERN1) |
Homo sapiens /
LINGO1/LRRN6A/LERN1 [Homo sapiens] |
IgG1-kappa |
| 10-259 |
Oportuzumab Monatox
(EPCAM/CD326) |
Humanized /
EPCAM/CD326 [Homo sapiens] |
scFv-kappa-heavy |
| 21-944 |
Opucolimab |
Humanized / PDL1 |
IgG1,Lambda |
| 10-159 |
Oregovomab
(MUC16/CA125) |
Mus musculus /
MUC16/CA125 [Homo sapiens] |
IgG1-kappa |
| 10-914 |
Orilanolimab
(FCGRT) |
Chimeric / FCGRT
[Homo sapiens] |
IgG4-kappa |
| 10-498 |
Orticumab (oxLDL) |
Homo sapiens /
oxLDL [Homo sapiens] |
IgG1-lambda |
| 10-917 |
Osocimab (F11) |
Homo sapiens / F11
[Homo sapiens] |
IgG1-kappa |
| 10-231 |
OST 577 (HBV) |
Homo sapiens / HBV
[Hepatitis B virus] |
|
| 10-257 |
Otelixizumab (CD3E) |
Chimeric,Humanized
/ CD3E [Homo sapiens] |
IgG1-lambda |
| 10-225 |
Otilimab
(CSF2/GM-CSF) |
Homo sapiens /
CSF2/GM-CSF [Homo sapiens] |
IgG1-lambda |
| 10-653 |
Otlertuzumab
(CD37/TSPAN26) |
Humanized /
CD37/TSPAN26 [Homo sapiens] |
VH-V-kappa-CH2-CH3 |
| 24-429 |
OX40L Antibody
[R4930 (Oxelumab)], Human IgG1 |
Oxelumab binds to
human OX40L, the ligand of OX40,
stimulatory receptor that is expressed on activated T cells, natural
killer (NK) cells and natural killer T (NKT) cells. |
IgG1 kappa |
| 24-430 |
OX40L Antibody
[R4930 (Oxelumab)], Rabbit IgG |
Oxelumab binds to
human OX40L, the ligand of OX40,
stimulatory receptor that is expressed on activated T cells, natural
killer (NK) cells and natural killer T (NKT) cells. |
IgG kappa |
| 10-441 |
Oxelumab
(TNFSF4/CD252) |
Homo sapiens /
TNFSF4/CD252 [Homo sapiens] |
IgG1-kappa |
| 10-585 |
Ozanezumab
(RTN4/NOGO) |
Humanized /
RTN4/NOGO [Homo sapiens] |
IgG1-nd |
| 10-468 |
Ozoralizumab
(ALB/TNFSF2/TNF-alpha/TNFA ) |
Humanized /
ALB/TNFSF2/TNF-alpha/TNFA [Homo sapiens] |
VH-VH'-VH |
| 21-945 |
Pacanalotamab |
Humanized /
TNFRSF17, CD3E |
Bispecific
scFv,Kappa;Lambda |
| 10-992 |
Pacmilimab
(CD274/PD-L1/B7-H1) |
Homo sapiens /
CD274/PD-L1/B7-H1 [Homo sapiens] |
IgG4-kappa |
| 10-271 |
Pagibaximab
(Staphylococcus epidermidis lipoteichoic acid) |
Chimeric /
Staphylococcus epidermidis lipoteichoic acid [Staphylococcus epidermidis] |
IgG1-kappa |
| 10-094 |
Palivizumab (RSV) |
Humanized / RSV
[Respiratory syncytial virus] |
IgG1-kappa |
| 10-723 |
Pamrevlumab
(CTGF/IGFBP-8) |
Homo sapiens /
CTGF/IGFBP-8 [Homo sapiens] |
IgG1-kappa |
| 10-232 |
Panitumumab (EGFR) |
Homo sapiens / EGFR
[Homo sapiens] |
IgG2-kappa |
| 10-264 |
Panobacumab
(Serotype IATS O12) |
Homo sapiens /
Serotype IATS O12 [Pseudomonas aeruginosa, Gram negative bacteria] |
IgM-kappa |
| 10-499 |
Parsatuzumab
(EGFL7) |
Humanized / EGFL7
[Homo sapiens] |
IgG1-kappa |
| 10-124 |
Pascolizumab (IL4) |
Humanized / IL4
[Homo sapiens] |
IgG1-kappa |
| 10-663 |
Pasotuxizumab
(CD3E/FOLH1) |
Chimeric,Humanized
/ CD3E/FOLH1 [Homo sapiens] |
(scFv-heavy-kappa)-(scFv-heavy-lambda) |
| 10-469 |
Pateclizumab
(LTA/TNFSF1) |
Humanized /
LTA/TNFSF1 [Homo sapiens] |
IgG1-kappa |
| 10-482 |
Patritumab (ERBB3) |
Homo sapiens /
ERBB3 [Homo sapiens] |
IgG1-kappa |
| 21-946 |
Pavunalimab |
Humanized / LAG3,
CTLA4 |
Bispecific
,IgG1,Kappa |
| 21-947 |
Pavurutamab |
Humanized /
TNFRSF17, CD3E |
Bispecific
scFv,Kappa;Lambda |
| 21-948 |
Pelgifatamab |
Homo sapiens /
FOLH1 |
IgG1,Kappa |
| 10-615 |
Pembrolizumab
(PDCD1/PD1/CD279) |
Humanized /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 21-949 |
Penpulimab |
Humanized / PDCD1 |
IgG1,Kappa |
| 10-696 |
Pepinemab (SEMA4D) |
Chimeric,Humanized
/ SEMA4D [Homo sapiens] |
IgG4-kappa |
| 10-572 |
Perakizumab (IL17A) |
Humanized / IL17A
[Homo sapiens] |
IgG1-kappa |
| 10-095 |
Pertuzumab
(ERBB2/EGFR2/CD340) |
Humanized /
ERBB2/EGFR2/CD340 [Homo sapiens] |
IgG1-kappa |
| 10-994 |
Petosemtamab
(EGFR/ERBB1/LGR5) |
Homo sapiens /
EGFR/ERBB1/LGR5 [Homo sapiens] |
IgG1-kappa |
| 10-096 |
Pexelizumab (C5) |
Humanized / C5
[Homo sapiens] |
scFv-nd-nd |
| 10-584 |
Pidilizumab
(PDCD1/CD279) |
Humanized /
PDCD1/CD279 [Homo sapiens] |
IgG1-kappa |
| 21-950 |
Pimivalimab |
Homo sapiens /
PDCD1 |
IgG4,Kappa |
| 21-951 |
Pimurutamab |
Humanized / EGFR |
IgG1,Kappa |
| 10-588 |
Pinatuzumab Vedotin
(CD22) |
Humanized / CD22
[Homo sapiens] |
IgG1-kappa |
| 10-573 |
Placulumab
(TNFSF2/TNF-alpha/TNFA) |
Homo sapiens /
TNFSF2/TNF-alpha/TNFA [Homo sapiens] |
[V-kappa]2-Fc |
| 10-952 |
Plamotamab
(CD3E/MS4A1) |
Chimeric,Humanized
/ CD3E/MS4A1 [Homo sapiens] |
IgG1-kappa /
scFv-h-CH2-CH3 |
| 21-953 |
Plonmarlimab |
Humanized / CSF2 |
IgG1,Kappa |
| 10-734 |
Plozalizumab
(CCR2/CD192) |
Humanized /
CCR2/CD192 [Homo sapiens] |
IgG1-kappa |
| 24-536 |
Podoplanin (MAP
tag) Antibody [PMab-1], Rabbit IgG |
This antibody was
raised by immunising rats with 14-residue synthetic peptide mpp3851, which
corresponds to amino acids 38-51 (GDGMVPPGIEDKIT) of the
platelet-aggregation-stimulating (PLAG) domain of mouse podoplanin. Spleen
cells were then harvested, and fused to P3U1 cells to generate stable
hybridomas. |
IgG kappa |
| 24-537 |
Podoplanin (MAP
tag) Antibody [PMab-1], Rat IgG2a |
This antibody was
raised by immunising rats with 14-residue synthetic peptide mpp3851, which
corresponds to amino acids 38-51 (GDGMVPPGIEDKIT) of the
platelet-aggregation-stimulating (PLAG) domain of mouse podoplanin. Spleen
cells were then harvested, and fused to P3U1 cells to generate stable
hybridomas. |
IgG2a kappa |
| 10-589 |
Polatuzumab Vedotin
(CD79B) |
Humanized / CD79B
[Homo sapiens] |
IgG1-kappa |
| 10-456 |
Ponezumab (APP
Abeta40) |
Humanized / APP
Abeta40 [Homo sapiens] |
IgG2-kappa |
| 21-952 |
Ponsegromab |
Humanized / GDF15 |
IgG1,Kappa |
| 10-836 |
Porgaviximab (Zaire
Ebola virus) |
Chimeric / Zaire
Ebola virus [Zaire ebolavirus] |
IgG1-kappa |
| 10-937 |
Pozelimab (C5) |
Homo sapiens / C5
[Homo sapiens] |
IgG4-kappa |
| 10-995 |
Praluzatamab
(ALCAM/CD166) |
Humanized /
ALCAM/CD166 [Homo sapiens] |
IgG1-kappa |
| 10-860 |
Prasinezumab (SNCA) |
Humanized / SNCA
[Homo sapiens] |
IgG1-kappa |
| 10-763 |
Prezalumab
(ICOSLG/B7-H2/B7RP-1/CD275) |
Homo sapiens /
ICOSLG/B7-H2/B7RP-1/CD275 [Homo sapiens] |
IgG2-kappa |
| 10-181 |
Priliximab (CD4) |
Chimeric / CD4
[Homo sapiens] |
IgG1-kappa |
| 10-590 |
Pritoxaximab (shiga
toxin type 1 B subunit) |
Chimeric / shiga
toxin type 1 B subunit [Escherichia coli] |
IgG1-kappa |
| 10-285 |
Pritumumab (VIM ) |
Homo sapiens / VIM
[Homo sapiens] |
IgG1-nd |
| 10-916 |
Prolgolimab
(PDCD1/PD1/CD279) |
Homo
sapiens,Chimeric / PDCD1/PD1/CD279 [Homo sapiens] |
IgG1-kappa-lambda |
| 21-954 |
Pucotenlimab |
Chimeric / PDCD1 |
IgG4,Kappa |
| 21-955 |
Quavonlimab |
Humanized / CTLA4 |
IgG1,Kappa |
| 10-961 |
Quetmolimab
(CX3CL1) |
Chimeric,Humanized
/ CX3CL1 [Homo sapiens] |
IgG2-kappa |
| 10-481 |
Quilizumab (IGHE) |
Humanized / IGHE
[Homo sapiens] |
IgG1-kappa |
| 10-247 |
Racotumomab
(Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3)
Mus musculus IgM-kappa monoclonal antibody P3) |
Mus musculus /
Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3)
Mus musculus IgM-kappa monoclonal antibody P3 [Homo sapiens] |
IgG1-kappa |
| 10-457 |
Radretumab (FN EDB) |
Homo sapiens / FN
EDB [Homo sapiens] |
[(scFv-heavy-kappa)-IGHE-CH4]2 |
| 10-126 |
Rafivirumab (RV) |
Homo sapiens / RV
[Rabies virus] |
IgG1-lambda |
| 21-956 |
Ragifilimab |
Humanized /
TNFRSF18 |
IgG1,Kappa |
| 10-642 |
Ralpancizumab
(PCSK9/NARC1/ PC9) |
Humanized /
PCSK9/NARC1/ PC9 [Homo sapiens] |
IgG2-kappa |
| 10-311 |
Ramucirumab
(KDR/CD309) |
Homo sapiens /
KDR/CD309 [Homo sapiens] |
IgG1-kappa |
| 10-802 |
Ranevetmab
(NGF/NGFB) |
Caninized /
NGF/NGFB [Mus musculus] |
IgG1-kappa |
| 10-098 |
Ranibizumab (VEGFA) |
Humanized / VEGFA
[Homo sapiens] |
Fab-G1-kappa |
| 10-888 |
Ravagalimab
(CD40/TNFRSF) |
Humanized /
CD40/TNFRSF [Homo sapiens] |
IgG1-kappa |
| 10-813 |
Ravulizumab (C5) |
Humanized / C5
[Homo sapiens] |
IgG2-G4-kappa |
| 10-277 |
Raxibacumab
(Anthrax protective antigen ) |
Homo sapiens /
Anthrax protective antigen [Bacillus anthracis] |
IgG1-lambda |
| 21-957 |
Recaticimab |
Humanized / PCSK9 |
IgG1,Kappa |
| 10-756 |
Refanezumab
(MAG/SIGLEC-4A) |
Humanized /
MAG/SIGLEC-4A [Homo sapiens] |
IgG1-kappa |
| 10-233 |
Regavirumab (HCMV) |
Homo sapiens / HCMV
[Human herpesvirus 6] |
IgG1-kappa |
| 10-870 |
Relatlimab
(LAG3/CD223) |
Homo sapiens /
LAG3/CD223 [Homo sapiens] |
IgG4-kappa |
| 10-958 |
Relfovetmab
(NGF/NGFB) |
Felinized /
NGF/NGFB [Felis catus] |
IgG1-kappa |
| 10-673 |
Remtolumab
(IL17A/TNFSF2/TNF-alpha/TNFA) |
Homo sapiens /
IL17A/TNFSF2/TNF-alpha/TNFA [Homo sapiens] |
[VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer |
| 10-291 |
Reslizumab (IL5) |
Humanized / IL5
[Homo sapiens] |
IgG4-nd |
| 10-997 |
Retifanlimab
(PDCD1/PD1/CD279) |
Chimeric,Humanized
/ PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 21-959 |
Revdofilimab |
Chimeric / TNFRSF4 |
IgG1,Kappa |
| 10-317 |
Rilotumumab (HGF) |
Homo sapiens / HGF
[Homo sapiens] |
IgG2-kappa |
| 10-742 |
Rinucumab (PDGFRB/
PDGFR-1/CD140b) |
Homo sapiens /
PDGFRB/ PDGFR-1/CD140b [Homo sapiens] |
IgG4-kappa |
| 21-960 |
Ripertamab |
Chimeric / MS4A1 |
IgG1,Kappa |
| 10-735 |
Risankizumab
(IL23A) |
Humanized / IL23A
[Homo sapiens] |
IgG1-kappa |
| 10-182 |
Rituximab (MS4A1) |
Chimeric / MS4A1
[Homo sapiens] |
IgG1-kappa |
| 10-761 |
Rivabazumab (PcrV) |
Humanized / PcrV
[Pseudomonas aeruginosa,Gram negative bacteria] |
Fab'-G1-kappa |
| 10-312 |
Robatumumab
(IGF1R/CD221 ) |
Homo sapiens /
IGF1R/CD221 [Homo sapiens] |
IgG1-kappa |
| 10-442 |
Roledumab (RHD) |
Homo sapiens / RHD
[Homo sapiens] |
IgG1-kappa |
| 10-918 |
Rolinsatamab (PRLR) |
Chimeric / PRLR
[Homo sapiens] |
IgG1-kappa |
| 10-879 |
Romilkimab
(IL13/IL4) |
Chimeric,Humanized
/ IL13/IL4 [Homo sapiens] |
[VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer |
| 10-479 |
Romosozumab (SOST) |
Humanized / SOST
[Homo sapiens] |
IgG2-kappa |
| 10-340 |
Rontalizumab
(IFNA1) |
Humanized / IFNA1
[Homo sapiens] |
IgG1-kappa |
| 10-799 |
Rosmantuzumab
(RSPO3) |
Humanized / RSPO3
[Homo sapiens] |
IgG1-kappa |
| 21-961 |
Rosopatamab |
Chimeric / FOLH1 |
IgG1,Kappa |
| 10-738 |
Rovalpituzumab
(DLL3) |
Humanized / DLL3
[Homo sapiens] |
IgG1-kappa |
| 10-319 |
Rovelizumab
(ITGAL/CD11a/ITGB2/CD18) |
Humanized /
ITGAL/CD11a/ITGB2/CD18 [Homo sapiens] |
IgG4-nd |
| 10-781 |
Rozanolixizumab
(FCGRT) |
Chimeric,Humanized
/ FCGRT [Homo sapiens] |
IgG4-kappa |
| 24-493 |
RSV Antibody
[RSHZ19 (Felvizumab)], Human IgG1 |
This antibody was
prepared by the humanization of an F
protein-specific murine MAb, RSV19. More specifically, molecular techniques
were used to insert the complementarity determining regions from murine RSV19
into a human IgG1 heavy and k light chain-variable domain framework. |
IgG1 kappa |
| 24-494 |
RSV Antibody
[RSHZ19 (Felvizumab)], Rabbit IgG |
This antibody was
prepared by the humanization of an F
protein-specific murine MAb, RSV19. More specifically, molecular techniques
were used to insert the complementarity determining regions from murine RSV19
into a human IgG1 heavy and k light chain-variable domain framework. |
IgG kappa |
| 21-865 |
RSV-neutralizing
Human (Am14) |
Humanized /
Respipatory syncytial virus |
Human IgG1 |
| 21-864 |
RSV-neutralizing
Human (D25) |
Humanized /
Respipatory syncytial virus |
Human IgG1 |
| 21-962 |
Runimotamab |
Humanized / ERBB2,
CD3E |
Bispecific
IgG1;Kappa;Kappa |
| 10-066 |
Ruplizumab (CD40LG) |
Humanized / CD40LG
[Homo sapiens] |
IgG1-kappa |
| 21-963 |
Sabatolimab |
Humanized / HAVCR2 |
IgG4,Kappa |
| 10-800 |
Sacituzumab
(TACSTD2) |
Humanized / TACSTD2
[Homo sapiens] |
IgG1-kappa |
| 10-443 |
Samalizumab (CD200) |
Humanized / CD200
[Homo sapiens] |
IgG2-G4-kappa |
| 10-898 |
Samrotamab (LRRC15) |
Chimeric,Humanized
/ LRRC15 [Homo sapiens] |
IgG1-kappa |
| 10-475 |
Sarilumab
(IL6R/CD126) |
Homo sapiens /
IL6R/CD126 [Homo sapiens] |
IgG1-kappa |
| 10-998 |
Sasanlimab
(PDCD1/PD1/CD279) |
Humanized /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 11-053 |
Satralizumab (IL6R) |
Humanized / IL6R
[Homo sapiens] |
IgG2-kappa |
| 10-161 |
Satumomab (TAG-72) |
Mus musculus /
TAG-72 [Homo sapiens] |
IgG1-kappa |
| 10-339 |
Secukinumab (IL17A) |
Homo sapiens /
IL17A [Homo sapiens] |
IgG1-kappa |
| 10-832 |
Selicrelumab
(CD40/TNFRSF5) |
Homo sapiens /
CD40/TNFRSF5 [Homo sapiens] |
IgG2-kappa |
| 10-956 |
Semorinemab (MAPT) |
Chimeric,Humanized
/ MAPT [Homo sapiens] |
IgG4-kappa |
| 10-940 |
Serclutamab (EGFR) |
Chimeric,Humanized
/ EGFR [Homo sapiens] |
IgG1-kappa |
| 10-586 |
Seribantumab
(ERBB3) |
Homo sapiens /
ERBB3 [Homo sapiens] |
IgG2-lambda |
| 10-999 |
Serplulimab
(PDCD1/PD1/CD279) |
Humanized /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-591 |
Setoxaximab
(Stx2/SLT-II) |
Chimeric /
Stx2/SLT-II [Escherichia coli] |
IgG1-kappa |
| 10-778 |
Setrusumab (SOST) |
Homo sapiens / SOST
[Homo sapiens] |
IgG2-lambda |
| 10-097 |
Sevirumab (HCMV) |
Homo sapiens / HCMV
[Human herpesvirus 6] |
IgG1-kappa |
| 21-964 |
Sibeprenlimab |
Humanized / TNFSF13 |
IgG2,Kappa |
| 10-296 |
Sibrotuzumab (FAP) |
Humanized / FAP
[Homo sapiens] |
IgG1-kappa |
| 10-335 |
Sifalimumab (IFNA1) |
Homo sapiens /
IFNA1 [Homo sapiens] |
IgG1-kappa |
| 10-313 |
Siltuximab (IL6) |
Chimeric / IL6
[Homo sapiens] |
IgG1-kappa |
| 10-574 |
Simtuzumab (LOXL2) |
Humanized / LOXL2
[Homo sapiens] |
IgG4-kappa |
| 10-919 |
Sintilimab
(PDCD1/PD1/CD279) |
Homo sapiens /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-088 |
Siplizumab
(CD2/LFA-2) |
Humanized /
CD2/LFA-2 [Homo sapiens] |
IgG1-kappa |
| 10-846 |
Sirtratumab
(SLITRK6) |
Homo sapiens /
SLITRK6 [Homo sapiens] |
IgG2-kappa |
| 10-470 |
Sirukumab (IL6 ) |
Homo sapiens / IL6
[Homo sapiens] |
IgG1-kappa |
| 10-632 |
Sofituzumab Vedotin
(MUC16/CA125) |
Humanized /
MUC16/CA125 [Homo sapiens] |
IgG1-kappa |
| 10-314 |
Solanezumab (APP
Abeta,soluble monomer) |
Humanized / APP
Abeta,soluble monomer [Homo sapiens] |
IgG1-kappa |
| 10-480 |
Solitomab
(CD3E/EpCAM) |
Mus musculus /
CD3E/EpCAM [Homo sapiens] |
(scFv-kappa-heavy)-(scFv-heavy-kappa) |
| 11-000 |
Sonelokimab
(ALB,IL17A) |
Humanized /
ALB,IL17A [Homo sapiens] |
VH-VH'-VH |
| 10-269 |
Sontuzumab
(MUC1/CD227) |
Humanized /
MUC1/CD227 [Homo sapiens] |
IgG1-nd |
| 21-965 |
Sotigalimab |
Humanized / CD40 |
IgG1,Kappa |
| 21-966 |
Sotrovimab |
Homo sapiens /
SARS-CoV-2 Spike RBD |
IgG1,Kappa |
| 21-878 |
Sotrovimab
(VIR-7831/GSK4182136) |
Humanized / Spike
glycoprotein [SARS-CoV-2] |
Human IgG |
| 10-852 |
Spartalizumab
(PDCD1/PD1/CD279) |
Humanized /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 10-920 |
Spesolimab (IL36RN) |
Chimeric,Humanized
/ IL36RN [Homo sapiens] |
IgG1-kappa |
| 10-228 |
Stamulumab
(MSTN/GDF-8) |
Homo sapiens /
MSTN/GDF-8 [Homo sapiens] |
IgG1-nd |
| 21-967 |
Sudubrilimab |
Humanized / CD274 |
IgG1,Kappa |
| 21-968 |
Sugemalimab |
Homo sapiens / PDL1 |
IgG4,Lambda |
| 10-162 |
Sulesomab (NCA-90) |
Mus musculus /
NCA-90 [Homo sapiens] |
Fab'-G1-nd |
| 10-777 |
Suptavumab (RSV
glycoprotein F) |
Homo sapiens / RSV
glycoprotein F [Respiratory syncytial virus] |
IgG1-kappa |
| 21-969 |
Surzebiclimab |
Humanized / HAVCR2 |
IgG1,Kappa |
| 10-884 |
Sutimlimab (C1S) |
Chimeric,Humanized
/ C1S [Homo sapiens] |
IgG4-kappa |
| 10-343 |
Suvizumab (HIV-1) |
Humanized / HIV-1
[Human immunodeficiency virus 1] |
IgG1-kappa |
| 21-851 |
Suvratoxumab |
Homo sapiens /
alpha toxin [Staphylococcus aureus] |
IgG1-kappa |
| 10-152 |
T10B9.1A-31 (T cell
receptor) |
Mus musculus / T
cell receptor [Homo sapiens] |
IgM-kappa |
| 10-471 |
Tabalumab
(TNFSF13B/CD257) |
Homo sapiens /
TNFSF13B/CD257 [Homo sapiens] |
IgG4-kappa |
| 10-921 |
Tabituximab (FZD10) |
Chimeric / FZD10
[Homo sapiens] |
IgG1-kappa |
| 10-130 |
Tadocizumab
(ITGA2B_ITGB3) |
Humanized /
ITGA2B_ITGB3 [Homo sapiens] |
Fab-G1-kappa |
| 10-676 |
Tafasitamab (CD19) |
Humanized / CD19
[Homo sapiens] |
IgG1-G2-kappa |
| 11-001 |
Tafolecimab (PCSK9) |
Homo sapiens /
PCSK9 [Homo sapiens] |
IgG2-kappa |
| 24-641 |
TAG-72 Antibody
[Minretumomab (CC49 )], Mouse IgG1 |
This antibody was
raised by immunising BALB/c mice with TAG-72 purified from LS-174T human
carcinoma xenograft. |
IgG1 kappa |
| 24-642 |
TAG-72 Antibody
[Minretumomab (CC49 )], Rabbit IgG |
This antibody was
raised by immunising BALB/c mice with TAG-72 purified from LS-174T human
carcinoma xenograft. |
IgG kappa |
| 10-845 |
Talacotuzumab
(CD123/IL3Ra) |
Homo sapiens /
CD123/IL3Ra [Homo sapiens] |
IgG2-kappa |
| 21-867 |
Talizumab |
Chimeric, Humanized
/ IgE |
IgG4-kappa-lambda |
| 10-286 |
Talizumab
(CD3E/GPRC5D) |
Chimeric,Humanized
/ CD3E/GPRC5D [Homo sapiens] |
IgG4-kappa-lambda |
| 10-942 |
Tamrintamab (DPEP3) |
Homo
sapiens,Chimeric / DPEP3 [Homo sapiens] |
IgG4-lambda |
| 10-252 |
Tanezumab (IGHE) |
Humanized / IGHE
[Homo sapiens] |
IgG1-nd |
| 10-598 |
Tarextumab (CD52) |
Caninized / CD52
[Homo sapiens] |
IgG2-kappa-lambda |
| 21-970 |
Tarlatamab |
Humanized / DLL3,
CD3E |
Bispecific
scFv;Kappa;Lambda |
| 11-013 |
Tavolimab (TNF- SF4
receptor I) |
Homo sapiens / TNF-
SF4 receptor I [Homo sapiens] |
TBP-1:tumor
necrosis factor (TNF) binding protein variant 1 |
| 21-971 |
Tebentafusp |
Humanized / CD3E |
Kappa |
| 21-972 |
Tebotelimab |
Humanized / PDCD1,
LAG3 |
Bispecific scFv
,IgG4;Kappa;Kappa |
| 10-156 |
Technetium (99Mtc)
Nofetumomab Merpentan (IL3RA/CD123) |
Humanized /
IL3RA/CD123 [Homo sapiens] |
IgG1-kappa |
| 10-935 |
Teclistamab (MS4A1) |
Mus musculus /
MS4A1 [Homo sapiens] |
Fab-G2b-kappa |
| 10-163 |
Tecnemab (CSPG4/HMW-MAA/CD3E/ERBB2) |
Mus
musculus,Humanized / CSPG4/HMW-MAA/CD3E/ERBB2 [Homo sapiens],toxin
[Clostridium perfringens] |
F(ab')2, Fab / Fab2
mix, IgG1-nd, F(ab')2-G1-kappa |
| 10-278 |
Tefibazumab
(Fibrin-binding surface epitope clumping factor A) |
Humanized /
Fibrin-binding surface epitope clumping factor A [Staphylococcus aureus] |
IgG1-kappa |
| 21-973 |
Telazorlimab |
Humanized / TNFRSF4 |
IgG1,Kappa |
| 10-333 |
Telimomab Aritox
(CD5 ) |
Mus musculus / CD5
[Homo sapiens] |
Fab-nd-nd |
| 10-793 |
Telisotuzumab
(MET/RCCP2) |
Humanized /
MET/RCCP2 [Homo sapiens] |
IgG1-kappa |
| 10-248 |
Tenatumomab
(TNC/HXB) |
Mus musculus /
TNC/HXB [Homo sapiens] |
IgG2b-nd |
| 10-289 |
Teneliximab
(CD40/TNFRSF5) |
Chimeric /
CD40/TNFRSF5 [Homo sapiens] |
IgG1-nd |
| 11-015 |
Teplizumab (CD3) |
|
|
| 10-894 |
Tepoditamab
(CD3E/CLEC12A) |
Homo sapiens /
CD3E/CLEC12A [Homo sapiens] |
IgG1-kappa |
| 10-348 |
Teprotumumab
(IGF1R/CD221) |
Homo sapiens /
IGF1R/CD221 [Homo sapiens] |
IgG1-nd |
| 10-686 |
Tesidolumab (C5) |
Homo sapiens / C5
[Homo sapiens] |
IgG1-lambda |
| 21-974 |
Tesnatilimab |
Homo sapiens /
KLRK1 |
IgG4,Kappa |
| 10-741 |
Tezepelumab (TSLP) |
Homo sapiens / TSLP
[Homo sapiens] |
IgG2-lambda |
| 10-867 |
Tibulizumab
(IL17A/TNFSF13B/CD257) |
Humanized /
IL17A/TNFSF13B/CD257 [Homo sapiens] |
IgG4-kappa-[scFv]2 |
| 10-954 |
Tidutamab (CD3
epsilon/SSTR2) |
Chimeric,Humanized
/ CD3 epsilon/SSTR2 [Homo sapiens] |
IgG1-kappa /
scFv-h-CH2-CH3 |
| 10-256 |
Tigatuzumab
(TNFRSF10B/CD262) |
Humanized /
TNFRSF10B/CD262 [Homo sapiens] |
IgG1-nd |
| 10-747 |
Tilavonemab (MAPT) |
Chimeric / MAPT
[Homo sapiens] |
IgG4-kappa |
| 10-581 |
Tildrakizumab
(IL23A) |
Humanized / IL23A
[Homo sapiens] |
IgG1-kappa |
| 21-975 |
Tilogotamab |
Humanized /
TNFRSF10B |
IgG1,Kappa |
| 11-003 |
Tilvestamab (PCSK9) |
Humanized / PCSK9
[Homo sapiens] |
IgG1-kappa |
| 10-841 |
Timigutuzumab
(ERBB2/EGFR2/CD340) |
Humanized /
ERBB2/EGFR2/CD340 [Homo sapiens] |
IgG1-kappa |
| 10-770 |
Timolumab
(AOC3/VAP1) |
Homo sapiens /
AOC3/VAP1 [Homo sapiens] |
IgG4-kappa |
| 11-004 |
Tinurilimab
(CEACAM6) |
Humanized / CEACAM6
[Homo sapiens] |
IgG1-kappa |
| 10-856 |
Tiragolumab
(TIGIT/VSIG9/VSTM3) |
Homo sapiens /
TIGIT/VSIG9/VSTM3 [Homo sapiens] |
IgG1-kappa |
| 21-976 |
Tirnovetmab |
Caninized / IL31
(Canine) |
IgG2,Kappa |
| 10-848 |
Tislelizumab
(PDCD1/PD1/ CD279) |
Humanized /
PDCD1/PD1/ CD279 [Homo sapiens] |
IgG4-kappa |
| 10-745 |
Tisotumab (F3
/CD142) |
Homo sapiens / F3
/CD142 [Homo sapiens] |
IgG1-kappa |
| 21-869 |
Tixagevimab |
Humanized / RBD
[SARS-CoV-2] |
Human IgG |
| 21-977 |
Tixagevimab |
Homo sapiens /
SARS-CoV-2 Spike RBD |
IgG1,Kappa |
| 24-183 |
TNF alpha Antibody
[cA2 (Infliximab)], Human IgG1 |
Purified
recombinant human TNF (rTNF). |
IgG1 kappa |
| 24-184 |
TNF alpha Antibody
[cA2 (Infliximab)], Rabbit IgG |
Purified
recombinant human TNF (rTNF). |
IgG kappa |
| 24-486 |
TNF alpha Antibody
[D2E7 (Adalimumab)], Human IgG1 |
This antibody was
generated by affinity maturation from the 2SD4 scFv, which in turn was
selected on human TNF alpha by guided phage-display technology, using the
murine anti-hTNF alpha antibody Mab32 as a template (c.f. also US Patent
6090382). |
IgG1 kappa |
| 24-487 |
TNF alpha Antibody
[D2E7 (Adalimumab)], Rabbit IgG |
This antibody was
generated by affinity maturation from the 2SD4 scFv, which in turn was
selected on human TNF alpha by guided phage-display technology, using the
murine anti-hTNF alpha antibody Mab32 as a template (c.f. also US Patent
6090382). |
IgG kappa |
| 11-011 |
Tocilizumab (
IL-6R) |
|
IgG1 |
| 10-815 |
Tomaralimab
(TLR2/CD282) |
Chimeric /
TLR2/CD282 [Homo sapiens] |
IgG4-kappa |
| 10-840 |
Tomuzotuximab
(EGFR) |
Chimeric / EGFR
[Homo sapiens] |
IgG1-kappa |
| 10-923 |
Toripalimab
(PDCD1/PD1/CD279) |
Humanized /
PDCD1/PD1/CD279 [Homo sapiens] |
IgG4-kappa |
| 21-978 |
Torudokimab |
Humanized / IL33 |
IgG4,Kappa |
| 10-596 |
Tosatoxumab (alpha
toxin) |
Homo sapiens /
alpha toxin [Staphylococcus aureus] |
IgG1-lambda |
| 10-164 |
Tositumomab
(MS4A1/CD20) |
Mus musculus /
MS4A1/CD20 [Homo sapiens] |
IgG2a-lambda |
| 10-612 |
Tovetumab (PDGFRA /
PDGFR2/ CD140a) |
Homo sapiens /
PDGFRA / PDGFR2/ CD140a [Homo sapiens] |
IgG2-kappa |
| 21-979 |
Tozorakimab |
Humanized / IL33 |
IgG1,Lambda |
| 10-192 |
Tralokinumab (IL13) |
Homo sapiens / IL13
[Homo sapiens] |
IgG4-lambda |
| 21-854 |
Trastuzumab |
Humanized / ERBB2
(HER2, Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic
lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2,
CD_antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor
tyrosine-protein kinase erbB-2, NGL) [Homo sapiens] |
Human IgG1 |
| 10-458 |
Tregalizumab (CD4) |
Humanized / CD4
[Homo sapiens] |
IgG1-kappa |
| 10-266 |
Tremelimumab
(CTLA4/CD152) |
Homo sapiens /
CTLA4/CD152 [Homo sapiens] |
IgG2-kappa |
| 10-725 |
Trevogrumab
(MSTN/GDF8) |
Homo sapiens /
MSTN/GDF8 [Homo sapiens] |
IgG4-kappa |
| 10-272 |
Tucotuzumab
Celmoleukin (EPCAM/CD326) |
Humanized /
EPCAM/CD326 [Homo sapiens] |
IgG1-nd |
| 24-276 |
Tumor associated
glycoprotein (TAG) 72 Antibody [B72.3 (Satumomab)], Mouse IgG1 |
Tumour-associated
glycoprotein 72 is a glycoprotein found on the surface of many cancer cells,
including ovary, breast, colon, and pancreatic cells. |
IgG1 kappa |
| 24-277 |
Tumor associated
glycoprotein (TAG) 72 Antibody [B72.3 (Satumomab)], Rabbit IgG |
Tumour-associated
glycoprotein 72 is a glycoprotein found on the surface of many cancer cells,
including ovary, breast, colon, and pancreatic cells. |
IgG kappa |
| 21-980 |
Tusamitamab |
Chimeric / CEACAM5 |
IgG1,Kappa |
| 10-190 |
Tuvirumab (HBV) |
Homo sapiens / HBV
[Hepatitis B virus] |
IgG1-lambda |
| 10-459 |
Ublituximab
(MS4A1/CD20) |
Chimeric /
MS4A1/CD20 [Homo sapiens] |
IgG1-kappa |
| 21-981 |
Uliledlimab |
Humanized / NT5E |
IgG1,Kappa |
| 10-641 |
Ulocuplumab
(CXCR4/CD184) |
Homo sapiens /
CXCR4/CD184 [Homo sapiens] |
IgG4-kappa |
| 21-983 |
Upifitamab |
Humanized / SLC34A2 |
IgG1,Kappa |
| 21-984 |
Urabrelimab |
Homo sapiens / CD47 |
IgG4,Kappa |
| 10-460 |
Urelumab
(TNFRSF9/CD137 ) |
Homo sapiens /
TNFRSF9/CD137 [Homo sapiens] |
IgG4-kappa |
| 10-281 |
Urtoxazumab
(Stx-2/SLT-II) |
Humanized /
Stx-2/SLT-II [Escherichia coli] |
IgG1-kappa |
| 10-193 |
Ustekinumab (IL12B) |
Homo sapiens /
IL12B [Homo sapiens] |
IgG1-kappa |
| 10-796 |
Utomilumab
(TNFRSF9/CD137) |
Homo sapiens /
TNFRSF9/CD137 [Homo sapiens] |
IgG2-lambda |
| 10-768 |
Vadastuximab
(CD33/SIGLEC3) |
Chimeric /
CD33/SIGLEC3 [Homo sapiens] |
IgG1-kappa |
| 21-985 |
Valanafusp |
Chimeric / INSR |
IgG1,Kappa |
| 21-986 |
Vanalimab |
|
IgG1,Lambda |
| 10-682 |
Vandortuzumab
Vedotin (STEAP1) |
Humanized / STEAP1
[Homo sapiens] |
IgG1-kappa |
| 10-613 |
Vantictumab (FZD) |
Homo sapiens / FZD
[Homo sapiens] |
IgG2-lambda |
| 10-665 |
Vanucizumab
(ANGPT2/VEGFA) |
Humanized /
ANGPT2/VEGFA [Homo sapiens], |
VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa |
| 10-290 |
Vapaliximab
(AOC3/VAP-1) |
Chimeric /
AOC3/VAP-1 [Homo sapiens] |
IgG2-kappa |
| 10-821 |
Varisacumab (VEGFA) |
Homo sapiens /
VEGFA [Homo sapiens] |
IgG1-kappa |
| 10-662 |
Varlilumab
(CD27/TNFRSF7) |
Homo sapiens /
CD27/TNFRSF7 [Homo sapiens] |
IgG1-kappa |
| 10-472 |
Vatelizumab (ITGA2) |
Humanized / ITGA2
[Homo sapiens] |
IgG4-kappa |
| 10-315 |
Vedolizumab
(ITGA4_ITGB7) |
Humanized /
ITGA4_ITGB7 [Homo sapiens] |
IgG1-kappa |
| 24-482 |
VEGF Antibody
[Bevacizumab], Human IgG1 |
Recombinant human
VEGF. |
IgG1 kappa |
| 24-483 |
VEGF Antibody
[Bevacizumab], Rabbit IgG |
Recombinant human
VEGF. |
IgG kappa |
| 11-014 |
Veltuzumab
( CD20 receptors) |
|
|
| 10-461 |
Vesencumab
(NRP1/VEGF165R extracellular domain) |
Homo sapiens /
NRP1/VEGF165R extracellular domain [Homo sapiens] |
IgG1-kappa |
| 10-953 |
Vibecotamab (CD3
epsilon/ IL3RA) |
Chimeric / CD3
epsilon/ IL3RA [Homo sapiens] |
IgG1-kappa /
scFv-h-CH2-CH3 |
| 11-005 |
Vibostolimab
(TIGIT/VSIG9/VSTM3) |
Humanized /
TIGIT/VSIG9/VSTM3 [Homo sapiens] |
IgG1-kappa |
| 21-987 |
Vilobelimab |
Chimeric / C5 |
IgG4,Kappa |
| 10-127 |
Visilizumab (CD3E) |
Humanized / CD3E
[Homo sapiens] |
IgG2-nd |
| 21-988 |
Vixarelimab |
Homo sapiens / OSMR |
IgG4-IgG1,Lambda |
| 21-989 |
Vixtimotamab |
Chimeric / CD3E,
CD33 |
Bispecific
Homodimer (VK-VH-VL'-VH', Tandem diabody);Kappa;Lambda |
| 10-933 |
Vofatamab (FGFR3) |
Humanized / FGFR3
[Homo sapiens] |
IgG1-kappa |
| 10-945 |
Volagidemab (GCGR) |
Homo sapiens / GCGR
[Homo sapiens] |
IgG2-kappa |
| 10-274 |
Volociximab
(ITGA5/CD49e) |
Chimeric /
ITGA5/CD49e [Homo sapiens] |
IgG4-nd |
| 10-772 |
Vonlerolizumab
(TNFRSF4/CD134) |
Humanized /
TNFRSF4/CD134 [Homo sapiens] |
IgG1-kappa |
| 10-883 |
Vopratelimab
(ICOS/CD278) |
Humanized /
ICOS/CD278 [Homo sapiens] |
IgG1-kappa |
| 10-575 |
Vorsetuzumab
(CD70/TNFSF7) |
Humanized /
CD70/TNFSF7 [Homo sapiens] |
IgG1-kappa |
| 21-990 |
Vudalimab |
Humanized / CTLA4,
PDCD1 |
Bispecific
,IgG1,Kappa;Kappa |
| 21-991 |
Vulinacimab |
Homo sapiens /
VEGFR2 |
IgG1,Kappa |
| 10-797 |
Vunakizumab (IL17A) |
Humanized / IL17A
[Homo sapiens] |
IgG1-kappa |
| 10-753 |
Xentuzumab
(IGF1/IGF2 ) |
Homo sapiens /
IGF1/IGF2 [Homo sapiens] |
IgG1-lambda |
| 10-131 |
Yfc51.1Mab
(ITGB2/CD18) |
Humanized /
ITGB2/CD18 [Homo sapiens] |
IgG1-nd |
| 10-132 |
Yth12.5 (CD3E) |
Humanized / CD3E
[Homo sapiens] |
IgG1-nd |
| 10-273 |
Yttrium (90Y)
Tacatuzumab Tetraxetan (AFP) |
Humanized / AFP
[Homo sapiens] |
IgG1-kappa |
| 11-008 |
Zagotenemab (MAPT) |
Humanized / MAPT
[Homo sapiens] |
IgG4-kappa |
| 10-948 |
Zalifrelimab
(CTLA4/CD152) |
Homo sapiens /
CTLA4/CD152 [Homo sapiens] |
IgG1-kappa |
| 10-236 |
Zalutumumab (EGFR) |
Homo sapiens / EGFR
[Homo sapiens] |
IgG1-kappa |
| 10-924 |
Zampilimab (TGM2) |
Chimeric,Humanized
/ TGM2 [Homo sapiens] |
IgG4-kappa |
| 21-992 |
Zanidatamab |
Humanized / ERBB2,
ERBB2 |
Bispecific
IgG1;Kappa;Kappa |
| 10-839 |
Zanidatamab
(ERBB2/EGFR2/CD340) |
Humanized /
ERBB2/EGFR2/CD340 [Homo sapiens] |
IgG1-kappa/scFv-h-CH2-CH3 |
| 10-238 |
Zanolimumab (CD4) |
Homo sapiens / CD4
[Homo sapiens] |
IgG1-kappa |
| 21-993 |
Zansecimab |
Humanized / ANGPT2 |
IgG4,Kappa |
| 11-009 |
Zelminemab
(ADCYAP1R1) |
Humanized /
ADCYAP1R1 [Homo sapiens] |
IgG1-kappa |
| 21-994 |
Zeluvalimab |
Humanized / PDCD1 |
IgG1,Kappa |
| 10-862 |
Zenocutuzumab
(ERBB2/ERBB3) |
Humanized /
ERBB2/ERBB3 [Homo sapiens] |
IgG1-kappa |
| 21-995 |
Zilovertamab |
Humanized / ROR1 |
IgG1,Kappa |
| 11-010 |
Ziltivekimab (IL6 ) |
Homo
sapiens,Humanized / IL6 [Homo sapiens] |
IgG1-kappa |
| 10-844 |
Zolbetuximab
(CLDN18) |
Chimeric / CLDN18
[Homo sapiens] |
IgG1-kappa |
| 10-329 |
Zolimomab Aritox
(CD5) |
Mus musculus / CD5
[Homo sapiens] |
IgG1-nd |
| 21-996 |
Zuberitamab |
Chimeric / MS4A1 |
IgG1,Kappa |